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 ABSTRACT  
 
Mary E Resseguie 
 
The Role of Gender and Genetic Polymorphisms in De Novo Choline Synthesis 
(Under the direction of Dr. Steven H. Zeisel)  
 
Choline is an essential nutrient for humans, though some of the requirement can be met 
by endogenous synthesis catalyzed by phosphatidylethanolamine N-methyltransferase 
(PEMT).  The human PEMT gene encodes three unique transcripts, A (NM_148172), B 
(NM_007169), and C (NM_148173) which encode two different protein isoforms.  
PEMT I, encoded by transcript A, localizes to the endoplasmic reticulum whereas PEMT 
II, synthesized from transcripts B and C, is found primarily in the mitochondrial 
associated membrane and is functionally distinct from PEMT I.  Studies in mammals 
indicate a connection between estrogen and protection against choline deficiency 
syndrome (CDS) but the nature of this interaction is not understood.  Examining the 
entire PEMT locus by chromatin immunoprecipitation coupled to microarray (ChIP-
chip), we identified several estrogen receptor-alpha (ER-α) enriched regions in the PEMT 
locus specifically implicating a critical regulatory region located in intron 1 of the A 
transcription start site, 7500 nucleotides (nt) upstream of the transcriptional start site of 
transcript B.  We found that PEMT transcription was increased in a dose-dependent 
manner when primary mouse and human hepatocytes were treated with 17-β-estradiol for 
24 hours and this increased message was associated with an increase in protein 
expression and enzyme activity.  ER-α regulation of the PEMT gene is transcript specific, 
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 whereby estrogen binding results in an increase in transcripts B and C but not transcript 
A.  We suggest that differences in dietary choline requirements occur between men and 
women because estrogen induces expression of the PEMT gene, allowing premenopausal 
women to make more choline endogenously. 
In humans, young women harboring a PEMT promoter SNP are 25X as likely to 
develop CDS as are non-carriers of this SNP.  Here we demonstrate, in human 
hepatocytes, that a haploblock of SNPs within a key estrogen regulatory region in the 
PEMT gene disrupt ER-α DNA binding.  Hepatocytes homozygous for the risk allele 
were not estrogen responsive.  For the first time, we report a putative mechanism 
underlying the association of PEMT genetic variation and susceptibility to choline 
deficiency syndrome in women. 
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CHAPTER I 
GENERAL INTRODUCTION
CHOLINE IS AN ESSENTIAL NUTRIENT 
Choline is a dietary component essential for normal function of all cells (Zeisel 
and Blusztajn, 1994).  It, or its metabolites, assures the structural integrity and signaling 
functions of cell membranes; it is the major source of methyl-groups in the diet 
(following its oxidation to betaine, it participates in the methylation of homocysteine to 
form methionine); and it is the precursor for the neurostransmitter acetylcholine; and it is 
involved in lipid transport from liver (Zeisel and Blusztajn, 1994).  Choline is particularly 
important during pregnancy because it has been implicated in fetal brain development.  
When rat dams received choline supplements (during days 12-17 of gestation), their 
offspring had significant and lifelong enhancement of spatial memory and attention with 
changes in hippocampal anatomy, chemistry, electrophysiology, neuronal stem cell 
proliferation and apoptosis (Albright et al., 2001; Albright et al., 1999; Craciunescu et al., 
2003; Loy et al., 1991; Meck and Williams, 1997a, b, c; Meck et al., 1988, 1989; Meck 
and Williams, 1999; Meck and Williams, 2003; Mellott et al., 2004; Montoya et al., 
2000; Pyapali et al., 1998).  Choline is widely distributed in all cells, mainly in the form 
of the phospholipids, phosphatidylcholine (PtdCho), lysophosphatidylcholine 
(lysoPtdCho), choline plasmalogen, platelet-activating factor, and sphingomyelin (SM), 
essential components of all eukaryotic cell membranes.  Choline can also be acetylated, 
phosphorylated, oxidized or hydrolyzed, and forms water-soluble choline metabolites, 
acetylcholine, phosphocholine (PCho), betaine, or glycerophosphocholine (GPCho).   
There are multiple functional consequences of dietary choline deficiency in 
humans, including the development of fatty liver (hepatosteatosis) (Buchman et al., 1995; 
Zeisel et al., 1991) because a lack of phosphatidylcholine (PtdCho) limits the export of 
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excess triglyceride from liver in lipoproteins (Yao and Vance, 1988, 1989).  Also, choline 
deficiency is associated with liver damage (elevated serum aminotransferases) (Albright 
et al., 2005; Albright et al., 1996; Albright and Zeisel, 1997; Zeisel et al., 1991) and liver 
dysfunction due to apoptosis of liver cells (Zeisel 1996) and massive accumulation of 
triacylglycerol (TG) within the hepatocyte in mammalian species (Zeisel 1991).  The 
phenotypic clinical manifestations associated with restricted dietary choline will 
subsequently be referred to as choline deficiency syndrome (CDS). 
PtdCho is made in all nucleated cells via the choline pathway.  The majority of 
PtdCho derives from pre-formed choline, with CTP: phosphocholine cytidylyltransferase 
(CCT) catalyzing the rate-limiting step in the CDP-choline pathway (Sundler 1972; Kent 
1997). (Figure 1-1)  
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Figure 1-1.  Pathways of Choline Metabolism  
Pathways involved in choline and phosphatidylcholine (PC) homeostasis: E, 
ethanolamine; P-E, phosphoethanolamine; CDP-E, CDP-ethanolamine; PE, 
phosphatidylethanolamine; SM, sphingomyelin.  Enzyme names are indicated by 
numbers: 1, choline acetyltransferase; 2, choline kinase; 3, CTP:phosphocholine 
cytidylyltransferase; 4, CDP-choline:1,2-diacylglycerol cholinephosphotransferase; 5, 
sphingomyelin synthase; 6, phosphatidylserine synthase 1; 7, phosphatidylserine 
decarboxylase; 8, phosphatidylethanolamine N-methyltransferase; 9, ethanolamine 
kinase; 10, CTP:phosphoethanolamine cytidylyltransferase; 11, CDP-ethanolamine:1,2 
diacylglycerol ethanolaminephosphotransferase; 12, various phospholipase and 
lysophospholipase activities; 13, sphingomyelinase; 14, choline oxidase; 15, betaine 
aldehyde dehydrogenase.
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CHOLINE BIOSYNTHESIS 
The only source of choline other than diet is from the de novo biosynthesis of 
PtdCho catalyzed by phosphatidylethanolamine-N-methyltransferase (PEMT; EC 
2.1.1.17).  PEMT, 20 kDa protein, is primarily found in the liver (Vance and Ridgway, 
1988).  PEMT spans the membrane with four transmembrane sequences (Shields et al., 
2003b).  The methyl donor for the methylation reactions is S-adenosylmethionine 
(AdoMet), which binds to several residues of PEMT exposed on the cytosolic surface of 
the endoplasmic reticulum (Shields et al., 2003a).  
The human PEMT gene, which is located on chromosome 17p11.2, has 9 exons 
and 8 introns spanning its 86 kb length, and it encodes three unique transcripts annotated 
by three Refseq accessions: A (NM_148172), B (NM_007169), and C (NM_148173) 
which make two different protein isoforms.  Each of the three transcript variants has only 
7 exons and 6 introns due to splicing of the leading exons, which are alternatively spliced 
to a common exon 2, where translation begins (Shields et al., 2001).  Each of the three 
leading exons is unique for transcript A, B, and C and thus will be referred to as exons 
1A, 1B, and 1C throughout the manuscript.  PEMTI, encoded by transcript A, localizes to 
the endoplasmic reticulum and transcripts B and C encode an isoform, PEMTII, which is 
localized to the mitochondrial associated membrane (a subfraction of the endoplasmic 
reticulum) (Cui et al., 1993). 
The significance of phosphatidylethanolamine methylation is only now being 
understood.  The CDP-Choline and PEMT pathways have distinct roles and are not 
interchangeable (DeLong et al., 1999).  Bile secretion or lipoprotein secretion may 
specifically require PEMT-derived PtdCho (Agellon et al., 1999; Li et al., 2005; Sehayek 
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et al., 2003).  PEMT is required for the secretion of apoB100-containing VLDLs (Noga et 
al., 2002).  The PEMT pathway generates PtdCho species that are much more diverse and 
enriched with long chain, and very long chain, polyunsaturated (e.g. 18:0/20:4) fatty 
acids.  In contrast, PtdCho derived from the CDP-choline pathway is mainly comprised 
of long chain saturated (e.g. 16:0/18:0) species (Magret et al., 1996). 
To explore the physiological importance of the PEMT pathway, mice that lack 
Pemt (Pemt–/–) were created by targeted deletion of exon 2 which contains the 
transcription start site (Walkey 1997).  When fed a choline-deficient (CD) diet, the mice 
rapidly developed steatosis, steatohepatitis, and died from liver failure after 3 days 
(Walkey et al., 1998).  The liver failure was associated with a 50% decrease in hepatic 
PtdCho content; thus, it was suggested that this was the reason for the steatohepatitis and 
liver failure.  Zhu et al found that Pemt–/– mice developed significant lipid accumulation 
and cell damage in liver despite having extra choline provided in their diet, and that 
condition was exacerbated during pregnancy (Zhu et al., 2003).  Pemt–/– mice have lower 
choline pools in liver despite being fed sufficient or supplemental amounts of dietary 
choline (Zhu et al., 2003).  Lipid analyses of plasma and liver indicated that male Pemt–/– 
mice accumulated triacylglycerols (TG) in their livers and were unable to secrete the 
same amount of TG from the liver as did Pemt+/+ mice (Noga and Vance, 2003).  
Another study found that cultured hepatocytes from Pemt–/–mice incubated with oleate 
secreted~50% less TG and ~70% less apoB100 than do hepatocytes from Pemt+/+ mice 
and although the total amount of PtdCho secreted was not altered in Pemt–/– hepatocytes, 
the PtdCho recovered in the VLDL fraction was decreased.  Thus, PEMT has a special 
function that is required for normal secretion of TG and apoB100 particles from 
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hepatocytes (Noga et al., 2002).  These results underscore the importance of the PEMT 
pathway as a significant and indispensible source of choline.   
ESTROGEN STATUS MAY MODULATE CHOLINE REQUIREMENT  
Gender is an important modifier of susceptibility to developing organ dysfunction 
when fed a low choline diet.  Premenopausal women, relative to males and 
postmenopausal women are resistant to developing organ dysfunction when fed a low 
choline diet (Fischer et al., 2007).  Interestingly, within each gender category, only a 
subset of subjects were found to be susceptible to developing organ dysfunction, 
suggesting that other factors, such as genetic polymorphisms, may contribute to 
susceptibility to developing organ dysfunction when fed a low choline diet.  It is 
reasonable to suggest that this protective effect observed in young women is due to an 
enhanced capacity for de novo biosynthesis of the choline moiety.  Studies in animal 
models support this hypothesis, as female rats are less prone to becoming symptomatic on 
a low choline diet due their ability to generate more PtdCho via the PEMT pathway as 
compared to male mice (Tessitore et al., 1995)  Female rats have greater PEMT 
enzymatic activity relative to male rats (Bjornstad and Bremer, 1966; Lindblad and 
Schersten, 1976; Lyman et al., 1971) and male castrated rats treated with estradiol have 
increased hepatic PEMT activity (Young, 1971).  Thus, estrogen could be the mediator of 
increased PEMT activity in humans.  
Pregnancy and lactation are times when demand for choline is especially high, 
thus it makes sense evolutionarily that women have adequate stores of choline prior to 
becoming pregnant (Sweiry et al., 1986; Sweiry and Yudilevich, 1985).  During 
pregnancy, estradiol concentration rises from approximately 1 nM during the first 
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trimester to 60 nM at term, allowing for maximum endogenous synthesis of choline 
during the period when females need to support fetal development (Adeyemo and 
Jeyakumar, 1993).  Transport of choline from mother to fetus depletes maternal plasma 
choline in humans (McMahon and Farrell, 1985).  Because milk contains a large quantity 
of choline, lactation further increases maternal demand for choline resulting in depleted 
tissue stores (Holmes-McNary et al., 1996; Zeisel et al., 1995).  Thus, choline availability 
during pregnancy and lactation is marginal despite enhanced capacity for endogenous 
biosynthesis of choline.  PEMT –/– mice abort pregnancies around day 9-10 of gestation 
unless fed supplemental choline (Zhu et al., 2004).  The same may be true for pregnant 
women eating too little choline.  Indeed, a study conducted by the March of Dimes 
reports that high periconceptional intake of choline and betaine reduced the risk of neural 
tube defects and cleft palate (Shaw et al., 2006; Shaw et al., 2004).  This group also 
reported that women in the United States consume <300 mg/d to >500 mg/d dietary 
choline (Shaw et al., 2004). 
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GENETIC POLYMORPHISMS AND CHOLINE REQUIREMENT 
Genetic polymorphisms are found throughout the genome.  Polymorphisms that 
affect the regulation of gene expression are critical to understanding human genetic 
differences in susceptibility to diseases and sensitivity to environmental exposures 
(Olivier, 2004; Pastinen et al., 2004).  Single nucleotide polymorphisms (SNPs), changes 
of a single DNA base, account for approximately 90% of human sequence variations and 
have been estimated to occur every 500–1000 base-pairs throughout the human genome 
(Collins et al., 1998; Sherry et al., 1999).  Apart from SNPs, other common 
polymorphisms include tandem repeated segments (minisatellite and microsatellites), and 
copy number variants (Ponomarenko et al., 2002).  SNPs that occur in coding regions 
(cSNPs) may alter the amino-acid sequence, resulting in changes in the structure and 
function of the encoded protein; whereas SNPs that affect gene expression levels in an 
allele-specific manner are generally found in gene regulatory regions. 
Polymorphisms in choline metabolism genes that affect enzymatic activity and 
transcriptional regulation could influence human requirements for the nutrient choline.  
SNPs in the PEMT gene could modify de novo PtdCho synthesis, thereby altering 
susceptibility to developing organ dysfunction when fed a low choline diet.  Ninety-eight 
SNPs were identified in PEMT from 48 Japanese individuals by direct sequencing of 
their entire genomic regions except for repetitive elements (Saito et al., 2001), but only 
one cSNP was found to be functionally significant (Song et al., 2005).  We recently 
reported that a PEMT B promoter SNP, rs12325817, was associated with increased 
susceptibility to CDS in women (da Costa et al., 2006).  Presumably rs12325817 affects 
transcriptional regulation of the gene or is in linkage disequilibrium (LD) with a SNP that 
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affects PEMT function.  The SNP was associated with CDS in women but not in men, 
suggesting that an estrogen regulatory mechanism is involved.  Premenopausal women 
homozygous for the SNP are sensitive, perhaps premenopausal women heterozygous for 
the rs12325817 risk allele have sufficient estrogen to overcome the effects on estrogen of 
the single allele, whereas postmenopausal women with lower estrogen levels are sensitive 
to the SNP and men, with no estrogen, are not sensitive to the SNP at all.  This promoter 
SNP does not fall within a mapped transcription factor binding site nor is it a HapMap (a 
catalog of common genetic variants that occur in human beings) SNP, which would 
permit, by imputation, identification of potential regulatory SNPs in linkage 
disequilibrium with rs12325817 (Frazer et al., 2007).  We propose studies to uncover the 
mechanism whereby rs12325817 or an associated SNP confers risk to CDS.  A cSNP that 
alters the tertiary structure of the active site in PEMT enzyme could potentially decrease 
the enzyme activity, and people with such a polymorphism would need extra choline for 
normal liver function.  Analogously, a regulatory SNP that affects PEMT gene expression 
could result in less PEMT message and subsequently less choline availability de novo.  
As discussed previously, SNPs that affect choline bioavailability during pregnancy could 
markedly increase a woman’s risk of having a baby with a birth defect.   
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ESTROGEN AND LIVER 
Estrogens have important roles in both males and females.  However, it has been 
reported that in postmenopausal women and in men, 17-β-estradiol (E2) is not a 
circulating hormone; rather, it is synthesized in a number of sites other than the ovaries 
such as breast, brain, and bone (Glass, 2006).  Thus, in postmenopausal women and in 
men estrogen biosynthesis in these sites depends on a circulating source of androgenic 
precursors such as testosterone.  Plasma steroid E2 levels are approximately 0.04 nmol/l 
and 0.10 nmol/l in post-menopausal women and men, respectively whereas in pre-
menopausal women levels range from 1.0 to 60nmol/l. (Adeyemo and Jeyakumar, 1993; 
Labrie et al., 2003) 
Estrogen biosynthesis is catalyzed by aromatase cytochrome P450, a microsomal 
member of the cytochrome P450 superfamily (Harada et al., 1990; Means et al., 1989).  
Estrogens induce cellular changes through several different mechanisms. In the 
“classical” mechanism of estrogen action, estrogens diffuse into the cell and bind to the 
estrogen receptor (ER), which is located in the nucleus.  This nuclear estrogen-ER 
complex binds to estrogen response element sequences directly –via a 13-bp palindromic 
repeat– or indirectly through protein-protein interactions with activator protein 1 (AP1) 
or Sp1 transcription factor (SP1) sites in the promoter region of estrogen-responsive 
genes.  Coregulatory proteins (coactivators or corepressors) are recruited to the promoter, 
which results in either an increase or decrease in gene expression.  Genomic mechanisms, 
which alter gene expression, typically occur over the course of hours.  In contrast, 
estrogen can act more quickly (within seconds or minutes) via “nongenomic” 
mechanisms, either through the ER located in or adjacent to the plasma membrane, or 
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through other non-ER plasma membrane–associated estrogen-binding proteins resulting 
in cellular responses such as increased levels of Ca2+ or NO, and activation of kinases 
(Deroo and Korach, 2006).  In addition, recent reports suggest “nontranscriptional” action 
mediated by ER situated in the plasma membrane through the p85/Akt pathway 
(Bjornstrom and Sjoberg, 2005).  The ER exists in 2 main forms, ER-α and ER-β, which 
have distinct tissue expression patterns in both humans and rodents (Mueller and Korach, 
2001). 
Significant progress has been made in defining the interactions between 
chromatin and a complex array of transcription factors involved in ER-mediated gene 
expression (Halachmi et al., 1994; Metivier et al., 2003; Shang et al., 2000).  Studies have 
revealed the the cyclical, combinatorial association of ER, p160 coactivators, histone 
acetyl transferases (HAT), and chromatin modifying molecules, such as p300/CBP and 
p/CAF, with gene promoters (Metivier et al., 2003; Shang et al., 2000).  Many gene 
expression profiling studies have been conducted in breast cancer cell lines and have 
identified potential ER target genes such as TFF-1 (pS2), EBAG9, and Cathepsin D. 
(Augereau et al., 1994; Berry et al., 1989; Ikeda et al., 2000).  Recently, chromatin 
immunoprecipitation coupled to microarrays (ChIP-chip) have been explored to pursue 
the identification of ER binding in the human genome in breast cancer cells (Carroll et 
al., 2005; Carroll et al., 2006; Kwon et al., 2007; Lin et al., 2007).  The results of these 
studies, which found that gene proximal-promoter regions are not the major sites of ER 
binding, dispute the classical mechanism of ER mediated regulation.  For example, one 
study found that only 5% of the mapped ER-α binding sites are located within 5 kb 
upstream of the transcriptional start sites of adjacent genes and the vast majority of the 
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ER-α sites were within intronic or distal locations (Lin et al., 2007).  This result suggests 
ER-α mediates transcriptional regulatory mechanisms over significant physical distances 
from the site of gene transcription.  Carroll et al. identified six ER-α binding sites within 
200kbp of the PEMT A promoter (Carroll et al., 2006).  Another genome-wide promoter 
ChIP-chip study performed in breast cancer cells, identified enrichment at PEMT 
promoter A (NM_148172) (Kwon et al., 2007).   
The liver is an estrogen-sensitive organ which primarily expresses ER-α.  Human 
liver from both males and females expresses ER-α (Rossini et al., 1989).  To date, only 
one study has been conducted to evaluate ER-α binding patterns in liver (Gao et al., 
2008).  In contrast to the studies conducted in human breast cancer cells, this group 
determined in mouse liver that almost 50% of ER-α binding regions overlap with genes 
including 8% overlap with exons (Gao et al., 2008).  Carroll and colleagues demonstrated 
that ER-α binding requires a Forkhead protein, FOXA1, at these ER-α sites, to mediated 
transcriptional regulation (Carroll et al., 2005).  FOXA transcription factors are integral 
components of transcriptional regulatory networks in mammalian liver (Odom et al., 
2004). 
Nonalcoholic fatty liver disease (NAFLD) encompasses a disease spectrum 
ranging from simple triglyceride accumulation in hepatocytes (hepatic steatosis) to 
hepatic steatosis with inflammation (steatohepatitis), fibrosis, and cirrhosis 
(Neuschwander-Tetri and Caldwell, 2003).  A “two-hit” model has been proposed to 
explain the progression of NAFLD to non-alcoholic steatohepatitis (NASH).  The “first 
hit” constitutes the deposition of triglycerides in the cytoplasm of the hepatocyte.  
Additional cellular events must occur (the “second hit”) such as inflammation, apoptosis 
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and fibrosis for the disease to progress to NASH.  NASH has become the second or third 
most common liver disease in outpatient hepatology practice in North America (James 
and Day, 1999).  The underlying molecular mechanism involving the progression of 
hepatic steatosis to NASH remains to be elucidated in humans (Browning and Horton, 
2004). 
It has been reported that in nonobese nondiabetic breast cancer patients treated 
with tamoxifen induces NASH and liver cirrhosis (Oien et al., 1999; Pratt et al., 1995).  
Tamoxifen is a potent antagonist of estrogen in liver and breast tissue, and estrogen is 
believed to be profoundly involved in hepatic lipid metabolism (Djouadi et al., 1998).  
Previous studies suggest that tamoxifen increased hepatic fat content by blocking 
estrogenic regulation of hepatic lipid homeostasis (Osman et al., 2007).  Estrogen 
replacement reverses the hepatic steatosis phenotype in the male aromatase knockout 
(ArKO) mouse (Hewitt et al., 2004).  Collectively, these findings suggest the 
involvement of estrogen deficiency in the development of liver steatohepatitis.  
 
 15
 SUMMARY  
Choline is an essential nutrient required for maintaining normal liver function and 
sustaining pregnancy and lactation.  PEMT is the only source of endogenous choline 
biosynthesis.  Genetic polymorphisms that affect PEMT gene function may contribute to 
susceptibility to nonalcoholic steatohepatitis and other liver related metabolic disorders 
especially within dietary choline deficient populations.  A subset of premenopausal 
women is resistant to choline-deficiency syndrome when fed a choline deficient diet.  
This protective mechanism observed in young women is critical during pregnancy and 
fetal development when choline stores are limiting.  We hypothesize that PEMT, the gene 
responsible for endogenous biosynthesis of choline, is regulated by estrogen and suggest 
that a plausible explanation for the mechanism in which young women are resistant to 
choline deficiency syndrome could involve estrogen-mediated induction of PEMT.  We 
propose studies to determine if the PEMT gene is regulated by estrogen in human liver 
and elucidate the mechanism whereby regulatory SNPs identified in our clinical studies 
affect estrogenic regulation of gene expression.  Women with SNPs which affect estrogen 
regulation of PEMT may be at risk for hepatosteotosis as well as aberrant pregnancy 
outcomes. 
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ABSTRACT 
Choline is an essential nutrient for humans, though some of the requirement can 
be met by endogenous synthesis catalyzed by phosphatidylethanolamine N-
methyltransferase (PEMT).  Pre-menopausal women are relatively resistant to choline 
deficiency compared to post-menopausal women and men.  Studies in animals suggest 
that estrogen treatment can increase PEMT activity. In this study we investigated whether 
the PEMT gene is regulated by estrogen. PEMT transcription was increased in a dose-
dependent manner when primary mouse and human hepatocytes were treated with 17-β-
estradiol for 24 hours. This increased message was associated with an increase in protein 
expression and enzyme activity. In addition, we report a region that contains a perfect 
estrogen response element (ERE) approximately 7.5 kb from the transcription start site 
corresponding to transcript variants NM_007169 and NM_148173 of the human and 
murine PEMT genes respectively, three imperfect EREs in evolutionarily conserved 
regions and multiple imperfect EREs in non-conserved regions in the putative promoter 
regions.  We predict that both the mouse and human PEMT genes have three unique 
transcription start sites which are indicative of either multiple promoters and/or 
alternative splicing.  This study is the first to explore the underlying mechanism of why 
dietary requirements for choline vary with estrogen status in humans.  
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INTRODUCTION 
Choline is an essential nutrient (Institute of Medicine and National Academy of 
Sciences USA, 1998); it is used to form cell membranes, it is the major source of methyl-
groups in the diet, and it is a precursor for biosynthesis of the neurotransmitter 
acetylcholine (Zeisel, 2006). Choline is critical during fetal development, when it 
influences stem cell proliferation and apoptosis, thereby altering brain structure and 
function (Albright et al., 1999b; Craciunescu et al., 2003; Loy et al., 1991; Meck and 
Williams, 2003a; Mellott et al., 2004). Similarly it influences neural tube development 
(Fisher et al., 2001; Shaw et al., 2004). In later life, choline deficiency causes fatty liver, 
liver damage and muscle damage (da Costa et al., 2004; da Costa et al., 2005) and 
reduces the capacity to handle a methionine load, resulting in elevated homocysteine (da 
Costa et al., 2005), a risk factor for cardiovascular disease (Guba et al., 1996). Though 
many foods contain choline (Zeisel et al., 2003a; Zeisel et al., 2003b), there is at least 2-
fold variation in dietary intake in humans (Fischer et al., 2005; Shaw et al., 2004). 
Choline can also be derived from de novo biosynthesis of phosphatidylcholine catalyzed 
by phosphatidylethanolamine N-methyltransferase (PEMT, EC 2.1.1.17) (Bremer and 
Greenberg, 1961; Vance et al., 1998). Most of this enzyme’s activity is in the liver 
(Vance et al., 1997).  
When fed a diet low in choline, premenopausal women were much less likely to 
develop choline-deficiency associated organ dysfunction compared to men or 
postmenopausal women (Fischer et al., 2007). This suggests that premenopausal women 
might have an enhanced capacity for de novo biosynthesis of choline. Such a finding 
would be important during pregnancy and lactation, when the demand for choline is 
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especially high because the transport of choline from mother to infant, via placenta or 
mammary gland, constitutes an extraordinary drain on maternal choline stores (Zeisel et 
al., 1995). 
Studies in animal models support this hypothesis.  Female rats are less sensitive to 
choline deficiency than are male rats (Tessitore et al., 1995) and female mice produce 
more phosphatidylcholine via the PEMT pathway than do male mice (Noga and Vance, 
2003). Estrogen status may be important for this increased PEMT activity; estradiol 
treatment increased PEMT activity in pituitary of rats (Drouva et al., 1986) as well as in 
liver of castrated-rats (Young, 1971) and PEMT activity in liver was increased in 
diethylstilbestrol treated roosters (Vigo and Vance, 1981b). Thus, estrogen-mediated 
increases in PEMT activity in humans could be an explanation for the lower dietary 
choline requirements of premenopausal women. 
  The mechanism whereby estrogen increases PEMT activity is not known.  In the 
present study, we report that estrogen treatment up-regulates the expression of this gene 
in both mouse and human primary hepatocytes, with resulting increases in PEMT enzyme 
activity and that there are motifs for estrogen response elements (EREs) in the promoter 
region(s) of the PEMT gene. 
METHODS AND METHODS 
Materials. All reagents were obtained from Fisher Scientific (Fair Lawn, NJ), unless 
otherwise noted.   
Animals. All animal procedures were approved by the University of North Carolina 
Institutional Animal Care and Use Committee.  Male C57BL/6J mice (5-7 weeks old) 
were obtained from Jackson Laboratories (Bar Harbor, ME) were housed  individually in 
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cages in a climate-controlled room (24oC) exposed to a 12-hr light cycle, fed AIN76A 
semipurified diet (Dyets, Bethlehem, PA ) and water ad libitum.   
Primary mouse hepatocyte isolation.  Mice were anesthetized (200 mg ketamine/kg and 
16 mg xylazine/kg) by subcutaneous injection, and the livers harvested. Hepatocytes 
were isolated from the livers by a modification of the method described previously 
(Morita et al., 1995). Briefly, the liver was perfused, through a needle aligned along the 
inferior vena cava, with buffer (pH 7.5)  containing 137 mmol/L NaCl, 5.4 mmol/L KCl, 
0.5 mmol/L NaH2PO4, 0.42 mmol/L Na2HPO4, 10 mmol/L HEPES, 0.5 mmol/L EGTA, 
4.2 mmol/L NaHCO3, and 5 mmol/L glucose; collagenase buffer, pH 7.5, contained 137 
mmol/L NaCl, 5.4 mmol/L KCl, 5 mmol/L CaCl2, 0.5 mmol/L NaH2PO4, 0.42 mmol/L 
Na2HPO4, 10 mmol/L HEPES, 0.15 g/L collagenase B (Boehringer Mannheim Corp, 
Indianapolis, IN), 0.05 g/L trypsin inhibitor, 4.2 mmol/L NaHCO3, and 0.016 mmol/L 
phenol red. The collagenase-perfused liver was then dissected, suspended in Hanks' 
solution (30 mL), and filtered through cheesecloth and a 100-µm nylon membrane to 
remove connective tissue debris and cell clumps. Hepatocytes were subjected to 
centrifugation (42 x g, 2 min at 4° C) and resuspended in Hanks solution, this was 
repeated 4x. Then hepatocytes were purified using density gradient centrifugation (45% 
Percoll solution, 42 x g for 10 min at 4° C). Cell viability, measured by trypan blue 
exclusion, was more than 90%. 
Preparation of estradiol-free serum for hepatocyte culture. Charcoal (Norit A, acid 
washed, Sigma-Aldrich, St. Louis, MO) was washed twice with cold sterile water 
immediately before use. A 5% charcoal-0.5% dextran T70 (Pharmacia-LKB, Uppsala, 
Sweden) suspension was prepared, and aliquots were centrifuged at 1600 x g for 10 min. 
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Supernatants were aspirated, and fetal bovine serum (Biomeda, Foster City, CA) was 
mixed with the charcoal pellets. This charcoal-serum mixture was kept in suspension by 
rolling at 4 cycles/min at 37°C for 1 hour. After centrifugation at 1600 x g for 20 min, the 
supernatant was passed through a 0.45µm filter (Nalgene, Rochester, NY). The charcoal 
stripped serum was then stored at -20°C until needed.  More than 99% of serum sex 
steroids are reported to be removed by this treatment (Soto and Sonnenschein, 1985).  
Murine hepatocyte culture. Primary mouse hepatocytes were maintained in DMEM/F12 
medium (GIBCO- BRL, Carlsbad, CA), supplemented with 10% fetal bovine serum 
(Biomeda, Foster City, CA) and antibiotics (100 U/ml penicillin and 100 µg/ml of 
streptomycin; Sigma-Aldrich, St. Louis, MO), at 37 °C in humidified air containing 5% 
CO2. Briefly, 1.5 X 106 cells were seeded onto 60 mm culture dishes  (BDBiosciences, 
Franklin Lakes, NJ), incubated in fresh medium for 24 h and then washed with 1× 
phosphate buffered saline (PBS) twice before further incubation in medium which 
contained 90% phenol red-free DMEM/F12 supplemented with 10% charcoal stripped 
E2-free serum for 48 h. This medium was used to effect growth factor deprivation 
(Berthois et al., 1986).  Cells then were treated with 0-100 nmol/L 17- β -estradiol 
(prepared and stored in phenol red-free DMEM/F12 at 73 µmol/L per manufacturer’s 
instructions; Sigma-Aldrich, St-Louis, MO). After 24 or 48 h incubation, cells were 
harvested for total RNA and separately for the preparation of the microsomal protein 
fraction for PEMT activity assay, respectively. 
Murine Pemt Relative real-time mRNA quantification. Total RNA was extracted from 
cells using TRIzol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
instructions. Primers and probes for murine Pemt and β-actin were designed using 
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JaMBW sofware (http://www.bioinformatics.org/JaMBW; Table 2-1). The Pemt probe 
was labeled with a reporter dye (FAM, 6-carboxyfluorescein) at the 5’ end and a 
quencher dye (TAMRA, 6-carboxytetramethyrhodamine) at the 3’ end. The β -actin 
probe was labeled with a reporter dye (TET, tetramethylrhodamine) at the 5’ end. 
Quantitation of Pemt and β-actin mRNA levels was performed by a real-time RT-PCR 
assay using an ABI prism 7700 sequence detection system (ABI, Foster City, CA). A 30 
µL reaction mixture contained 500 ng of total RNA and 0.5 µmol/L of each primer. The 
reaction conditions were designed as follows: reverse transcription (RT) at 48°C for 30 
min and initial denaturation at 95°C for 10 min followed by 40 cycles with 15s at 95°C 
for denaturing and 1 min at 60°C for annealing and extension. Relative quantification of 
Pemt mRNA expression was calculated by the comparative threshold (Ct) method 
described elsewhere (Livak and Schmittgen, 2001). The relative quantification value of 
the target gene, normalized to an endogenous control gene and relative to a calibrator, 
was expressed as 2-∆∆Ct (Power/folds), where ∆Ct = Ct of target gene (Pemt) – Ct of 
endogenous control gene (β-actin), and ∆∆Ct = ∆Ct of samples for target gene (estrogen 
treatment) - ∆Ct of the calibrator (without estrogen treatment, negative control) for the 
Pemt gene.  Final results are expressed as mean ratio of Pemt expression for each 
estrogen treatment normalized to Pemt gene expression without estrogen.  
Murine Pemt Immunoblot. 50 µg of protein was separated by SDS-polyacrylamide gel 
electrophoresis on a 12.5% polyacrylamide gel and transferred to a polyvinylidene 
difluoride membrane (Sigma-Aldrich, St-Louis, MO), which was probed with anti-Pemt 
antibody (a kind gift from Dr. Dennis E. Vance), washed extensively, and then probed 
with horseradish peroxidase-conjugated goat anti-rabbit IgG (Pierce, Rockford, IL). 
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Table 2-1.  Real-Time PCR primers and probes used for gene expression analysis.  
Primers and probes for murine Pemt and β-actin were designed using JaMBW sofware 
(http://www.bioinformatics.org/JaMBW.  The Pemt probe was labeled with a reporter 
dye (FAM, 6-carboxyfluorescein) at the 5’ end and a quencher dye (TAMRA, 6-
carboxytetramethyrhodamine) at the 3’ end. The β -actin probe was labeled with a 
reporter dye (TET, tetramethylrhodamine) at the 5’ end.  PCR primers for human PEMT, 
Proteinase Inhibitor-9 (PI-9; positive control) and Tata-box Binding Protein (TBP; 
housekeeping gene) were designed using online Gene Fisher interactive primer design 
software (http://bibiserv.techfak.uni- bielefeld.de/genefisher/.  aPrimer binds all three 
Pemt transcript variants.
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Gene GenBank Accession # Forward Primer Reverse Primer bp 
Murine Gene Expression 
Probe 
Pemt1 NM_008819 ACTCATGCATGCTAGTCCA 
AGCAGTGAAGGG
CTCTTCAT 178 
5'-FAM-CGAGACAATTG 
CCACCAGCACGT-3' 
β-actin NM_007393 CTGCCTGACGGCCAAGTC 
CAAGAAGGAAGG
CTGGAAAAA 220 
5'-TET-CACTATTGGCA 
ACGAGCGGTTCCG-3' 
NM_148172 
NM_007169 PEMT1
NM_148172 
AAGACCCGCAA
GCTGAGA 
AGTACATGGGGT
TGTCCAGA 298 Not applicable 
TBP NM_003194 TTCGGAGAGTTCTGGGAG 
TGGACTGTTCTT
CACTCTTGC 227 Not applicable 
PI-9 L40378 GTGGCAGGCCCTGCATCA 
CACCCTTTATGG
CGATGA 271 Not applicable 
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Pemt protein was visualized by a reaction with Supersignal chemiluminescent substrate 
(Pierce) and exposed to X-ray film (Denville Scientific, Metuchen, NJ).  
Human hepaocyte isolation.   Primary human liver cells were provided as a gift by Admet 
Technologies (Durham, NC). They used donated livers not suitable for orthotopic liver 
transplantation obtained from federally designated organ procurement organizations. 
Informed consent was obtained from next of kin for use of the livers for research 
purposes.  Isolation of hepatocytes was performed by members of the Admet 
Technologies research team as described previously (LeCluyse et al., 2005).  These 
hepatocytes were transferred to us and used within 96 h of isolation. 
Human hepatocyte culture.  Cells were plated at a density of approximately 1.8 x 106 
cells per well on collagen-coated 6-well culture plates (BDBiosciences,  Franklin Lakes, 
NJ) and incubated for 6 h at 37˚C in humidified air containing 5% CO2 in William's 
complete medium E (WCME; GIBCO-BRL, Carlsbad, CA) containing 10% Dextran-
treated charcoal stripped fetal bovine serum (Biomeda, Foster City, CA) and antibiotics 
(100 U/ml penicillin and 100 µg/ml streptomycin; Sigma-Aldrich, St-Louis, MO). 
Medium was replaced at 6 h with serum-free WCME. Following a 48 h “recovery 
period” in serum-free WCME, human primary cells were incubated for 24 h in WCME 
with 0-1000 nmol/L 17- β -estradiol (prepared and stored per manufacturer’s 
instructions). After 24 or 48 h incubation, cells were harvested for cytoplasmic RNA and 
the total cellular protein fraction for the PEMT activity assay, respectively. 
Human PEMT mRNA quantification. Cytoplasmic RNA from liver cells was extracted 
using the RNeasy mini kit (Qiagen, Valencia, CA).  PCR primers for human PEMT, 
Proteinase Inhibitor-9 (PI-9; positive control) and Tata-box Binding Protein (TBP; 
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housekeeping gene) were designed using online Gene Fisher interactive primer design 
software (http://bibiserv.techfak.uni- bielefeld.de/genefisher/; Table 1) and purchased 
from Operon (Germantown, MD).  Real-time PCR reactions were performed using 100 
ng RNA, 0.5 µmol of each primer, and the one-step QuantiTect SYBR Green RT-PCR kit 
(Qiagen, Valencia, CA) in a 40 µL reaction. The reaction conditions were designed as 
follows: RT at 50°C for 30 min and PCR initial activation step at 95oC for 15 min. Initial 
denaturation at 94°C for 15 sec was followed by 40 cycles of annealing (58oC for 30 sec) 
and extension (72oC for 30 sec). Changes in PEMT mRNA levels were detected using an 
iCycler iQ Real-Time PCR Detection System (BioRad, Hercules, CA). Relative 
quantification of PEMT mRNA expression was calculated by the Ct method as described 
earlier and final results expressed as ratio change relative to untreated and normalized for 
Tata-Box Binding Protein (TBP). We used expression of the protease inhibitor 9 (PI-9) 
gene, known to be estrogen responsive (Kanamori et al., 2000), as a positive control (data 
not shown). 
PEMT protein expression and activity assay. Mouse and human hepatocytes were 
harvested 48 h after 17- β -estradiol treatment with two washes of 1X PBS, scraped into 
Medium 1 (250 mmol/L sucrose, 10 mmol/L Tris, pH 7.4, 1 mmol/L EDTA, and 1 
mmol/L dithiothreitol) and homogenized with 10 complete strokes in a Teflon-glass 
homogenizing vessel. For the murine cellular homogenate, an aliquot of total cellular 
homogenate was then centrifuged at 100,000 x g for 1 h to obtain total particulate 
(membrane) fraction. 50 µg of total murine particulate protein was used for PEMT 
activity assays as described previously using phosphatidylmonomethylethanolamine 
(PDME; Avanti Polar Lipids, Alabaster, AL) as the methyl acceptor and S-adenosyl-L-
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[methyl-3H] methionine (American Radiolabeled Chemicals Inc, St. Louis, MO) as the 
methyl group donor (Audubert and Vance, 1983).  
Comparative bioinformatics promoter analysis:   
CAGE analysis. CAGE analysis (Cap Analysis Gene Expression) data was retrieved from 
the FANTOM3 website (http://fantom.gsc.riken.go.jp/). CAGE analysis (Shiraki et al., 
2003) was used to identify the major transcription start sites (TSS) for the mouse and 
human PEMT gene. 
EST abundance of various PEMT transcripts. The positions of expressed sequence tag 
(EST) sequences  from the NCBI dbEST (http://www.ncbi.nlm.nih.gov/dbEST/; last 
accessed on 01/03/07) were displayed relative to the mouse and human PEMT gene of 
the Mouse and Human genome (May 2004 release) using the GenomBench tool of 
Vector NTI 10.1 (Invitrogen, Carlsbad, CA). All potentially full length ESTs were 
selected and found to group into three clusters, differing in the 5’ start of the ESTs for 
both human and mouse.  
Identification of Evolutionarily Conserved Regions (ECRs) and conserved transcription 
factor binding sites.  The analysis of human and mouse syntenic relationships and 
conservation profiles was done through the annotation of ECRs in the alignments of 
genomes. We employed the BLASTZ-based genome alignments generated by the ECR 
Browser (http://ecrbrowser.dcode.org; last accessed 01/03/07) (Ovcharenko et al., 2004). 
A genomic interval was annotated as an ECR if it was >100 bp and >70% identity as 
defined by the number of nucleotide matches in a sliding window (default settings). 
Prediction of potential conserved transcriptional binding sites was then done using the 
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rVista 2.0 search tool within the ECR Browser. The Transfac V10.2 database was used to 
scan these ECRs using default settings. 
Estrogen Response Element identification. EREs were identified with detection 
parameters set on the basis of optimized settings for the Dragon ERE Finder 
(http://sdmc.lit.org.sg/ERE-V2/index; last accessed 01/03/07) using the default 83% 
sensitivity (Bajic et al., 2003). Conserved EREs were identified as elements present in 
both the human and mouse PEMT gene at distances comprised between –10 to +15 kb 
from their respective transcription start sites (TSS A, TSS B, TSS C) 
Data Analysis: Prior to analysis, all data was normalized to the 0 nmol/L estrogen 
treatment for each individual (mouse and human). Data were expressed as mean ratio 
change of each estrogen treatment versus no treatment ± SE. Ratios were transformed to 
a log(2) scale to ensure normal distribution of the data, required by the parametric testing 
assumptions. Protein expression and gene expression significance of change statistical 
differences were assessed by one-way analysis of variance (ANOVA) followed by the 
Tukey-Kramer (P<0.05) multiple comparison test (JMP Version 3.2, SAS Institute Inc, 
Cary, NC).  Logistic regression analysis was performed to assess the trend significance of 
the dose response to estrogen (JMP Version 3.2), using ratio values. Linear Fit was used 
to determine the correlation between PEMT gene expression and activity, using only the 
points that have both gene expression and activity data. 
RESULTS 
Estrogen up-regulates murine Pemt gene expression, protein levels and enzyme activity.  
In mouse hepatocytes gene expression, protein expression and activity all were 
significantly increased by 17- β -estradiol treatment (Figure 2-1) and there was a strong 
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Figure 2-1 Estrogen induces Pemt gene and protein expression and increases 
enzyme activity in primary cultured mouse hepatocytes. Primary mouse hepatocytes 
were incubated with 17-β-estradiol (0-100 nmol/L) for 24 h before harvesting. A, 
Detection of Pemt and β-actin mRNA levels was performed by a real-time RT-PCR 
assay. Relative quantification of Pemt mRNA expression was calculated by the 
comparative threshold cycle (Ct) method as described in ”Experimental Procedures”.  
Results are expressed as mean ratio change in gene expression + SEM. (n=3/point).  
*=P<0.05 different from no treatment.  B, Total particulate protein was isolated and 
analyzed for PEMT protein expression by Western blotting as described in “Experimental 
Procedures”. Equal protein loading of lanes was assessed by Coomasie Blue gel staining 
(data not shown). C, Pemt enzyme activity was assayed by a radio-enzymatic assay as 
described in “Experimental Procedures”.  Results are expressed relative to no treatment 
as mean ratio change +  SEM. (n= 3/point).  *=P<0.05 different from no treatment.   
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dose-response relationship for both activity (EC50= 1nmol/L; p<0.0001) and gene 
expression (EC50= 5 nmol/L; p<0.0001).  Additionally, there was a strong correlation 
between gene expression and activity (correlation coefficient = 0.91).  
Estrogen up-regulates human PEMT gene expression and enzyme activity.  In human 
hepatocytes gene expression and activity were significantly increased by 17- β -estradiol 
treatment (Figure 2-2) and there was a strong dose-response relationship for both activity 
(EC50= 1nmol/L; p<0.0006) and gene expression (EC50= 10 nmol/L; p<0.0001) using 
logistic regression analysis. Gene expression and activity further increased at 1000 
nmol/L estrogen treatment (data not shown). However, a linear fit model suggests that 
there is only a weak correlation between PEMT gene expression and activity (0.34).  
Characterization of the Major Human and Mouse PEMT transcripts.  The human PEMT 
gene, which is located on chromosome 17p11.2, has 9 exons and 8 introns spanning its 86 
kb length, and it encodes three variant transcripts 
(http://www.ensembl.org/Homo_sapiens/geneview?gene=OTTHUMG00000059290;db=
vega, date last accessed 1/02/07).  Each of the three transcript variants has only 7 exons 
and 6 introns due to splicing of the leading exons 1-3, which are alternatively spliced to a 
common exon 4, where translation begins. (Shields et al., 2001). Three RefSeq 
accessions have been annotated for the human PEMT gene by NCBI, NM_148172, 
NM_007169, and NM_148173.  Murine Pemt, located on chromosome 11, has been 
reported to have 7 exons and 6 introns spanning approximately 75 kb and encoding one 
major transcript, annotated by NCBI RefSeq accession NM_008819. 
(http://www.ensembl.org/Mus_musculus/geneview?gene=OTTMUSG00000005808;db=
vega, date last accessed 1/02/07) (Walkey et al., 1996).  Primer extension analysis of the
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Figure. 2-2  Estrogen induces PEMT gene expression and increases enzyme activity 
in primary cultured human hepatocytes. Primary human hepatocytes from various 
donors were incubated with 17-β estradiol (0-100 nmol/L) for 24 h before harvesting. A, 
Detection of PEMT and Tata-Box Binding Protein (TBP) mRNA levels was performed 
by a real-time RT-PCR assay. Relative quantification of PEMT mRNA expression was 
calculated by the comparative threshold cycle (Ct) method described in “Experimental 
Procedures”.  Results are expressed as ratio fold change in gene expression relative to 
untreated samples +  SEM. (n= 4-5/point).  B, PEMT enzyme activity was assayed by a 
radio-enzymatic assay as described in “Experimental Procedures”.  Results are 
expressed as ratio change in enzyme activity (pmol/mg protein/min) relative to untreated 
samples +  SEM. (n= 4-7/point).  *=P<0.05 different from no treatment. 
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 murine Pemt gene demonstrated experimentally that the major Pemt TSS is located 139 
bp upstream of the initiator methionine codon (Walkey et al., 1996).  Human and murine 
PEMT proteins are 80% homologous, but unlike its human counterpart, murine Pemt 
protein translation initiation begins in exon 2.  It was previously reported that the 
transcript that begins with exon 2 [NM_007169] is the most abundant in human liver and 
that only one transcript [NM_008819] exists for the mouse Pemt gene (Shields et al., 
2001; Walkey et al., 1996).  
To more fully characterize the various alternative TSS in the human and mouse 
PEMT orthologs, we estimated the relative abundance of the major PEMT transcripts in 
human and mouse liver based on the ESTs in dbEST and used FANTOM3 CAGE 
analysis viewer to ascertain the location of the various TSS (Figure 2-3). Using publicly 
available data from dbEST we found that the vast majority of the 5’ ends of the ESTs 
cluster around the start point of NM_148172 (bp 17,435,719 of ch. 17) (denoted as 
human TSS A), suggesting that this is the most abundant transcript in the liver for the 
human PEMT gene.  This TSS is independently confirmed by the results of the 
FANTOM CAGE analysis where the representative CAGE TSS for the PEMT gene is at 
bp 17,435,731, 12 bp upstream of the RefSeq defined start. For NM_007169 (start 
defined at bp 17,426,470) (denoted as human TSS B), a representative CAGE TSS is 
found 40 bp upstream at bp 17,426,510. For NM_148173 (start defined at bp 17,421,504) 
(denoted as human TSS C), a representative CAGE start is found at bp 17,421,107 while 
the start based on the average of ESTs is 17,421,043; both are several hundred basepairs 
downstream of the RefSeq defined start.  
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Figure 2-3.  Comparative analysis of murine and human PEMT gene promoters.  
A. 500 kbp alignment of conserved syntenic blocks of human chromosome 17 and mouse 
chromosome 11, with blue boxes showing the relationships between orthologous genes. 
B. A 20kbp enlargement of the human PEMT gene encoded on the minus strand, the 
promoter region and the mouse orthologous region. The PEMT gene promoter region of 
the human and mouse contains six distinct evolutionarily conserved regions (ECR 1-ECR 
6). ECR 4 in murine Pemt has been translocated to a different chromosome (data not 
shown). There are three conserved estrogen response elements within ECR 5 and 6, 
shown as dark blue boxes, and a perfect consensus ERE in a distal promoter/enhancer 
region approximately 7.5kb from transcription start site (TSS) B, shown as hatched blue 
boxes with red outline.  Block arrow bars displayed beneath PEMT gene promoter 
regions represent the major transcripts relative to TSS A, B, C, (indicated by yellow-
green arrows) with the percentages reflecting the EST abundance of each transcript in 
liver (purple arrows indicate minor transcripts; red indicates the major transcript.  
Beneath the transcript arrow bars is shown a representative CAGE analysis for the major 
human and mouse TSS.  The highest peak, shown in red, represents the predominant TSS 
for the PEMT gene. Lower peaks around the major TSS (s) would represent some 
variation in the actual in vivo TSS.   aMotif Abbrevations for gene names are from 
LocusLink (www.ncbi.nlm.nih.gov/LocustLink/list.cgi; last accessed 01/02/07 
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We also suggest that the mouse Pemt gene has two previously unreported transcripts 
(denoted murine transcripts A and C) in addition to the previously described transcript, 
NM_008819 (denoted murine transcript B), which is also the most abundant transcript 
based on the abundance of ESTs in dbEST. The majority of the 5’ ends of the available 
ESTs (the EST average start; 59,649,465) cluster around the start point of NM_008819 
(bp 59,649,379 of ch. 11) (denoted murine TSS B), while CAGE analysis predicts the 
representative TSS at bp 59,649,447, which is 68 bp upstream of the RefSeq defined start 
for NM_008819. Available EST data suggest two additional mouse transcripts, transcript 
A, initiating approximately 9 kp upstream of NM_008819 and transcript C, initiating 
approximately 5 kb downstream. A representative CAGE TSS for transcript A is at 
59,659,083, denoted murine TSS A, while the EST average start suggests a start at 
59,658,975, within 108 bp of the CAGE start. For transcript C a representative CAGE 
TSS is at 59,644,334, denoted murine TSS C, and with the EST average start position is 
59,644,300. Thus, based on both EST sequences from dbEST and from CAGE analysis 
from the FANTOM3 database we conclude that both the mouse and human PEMT genes 
have three unique transcription start sites which are indicative of multiple promoters.  
While the identification of two additional transcripts in the mouse gene suggests 
conserved transcriptional regulation between species, it is interesting to speculate why 
transcript variant B (NM_008819) is the more abundant transcript in mice whereas 
transcript variant A (NM_148173) is more abundant in humans. 
Initial analysis of the human PEMT putative promoter B sequence for the exon-2 
containing transcript , NM_007169,  suggested that it contained transcription factor 
binding sites critical for SREBP and C/EBP; however, promoter B lacks core promoter 
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elements such as a TATA or CCAAT boxes (Shields et al., 2001).  We report that the 
region upstream of putative promoter A, exon-1 containing and the most abundant 
transcript variant NM_148172, contains a CpG island as well as core promoter elements 
including an experimentally validated 600 bp RNA polymerase II binding site (Pol 9419, 
p<0.00001) (Figure 2-3, Table 2-2)(Carroll et al., 2006). 
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Table 2-2.  Human and Mouse Conserved Promoter Motifs. For both human and 
mouse PEMT genes motif chromosomal position is displayed relative to transcription 
start site B (TSS B) (+1) based on the literature defined major TSS for each (Shields et 
al., 2001; Walkey et al., 1996); +/- indicates upstream or downstream orientation, 
respectively.  For the human +1 site, this corresponds to bp 17,426,514 of ch17. For 
mouse this corresponds to bp 59,649,481 on ch11 (UCSC May 2004 Release of the Mus 
musculus genome, mm5) which corresponds to bp 59,853,136 in the current release of 
the M. musculus genome (mm8). The mouse and human PEMT gene promoters are 
highly conserved in six distinct evolutionarily conserved regions (ECR 1-ECR 6). ECR 4 
in mouse Pemt has been translocated to a different chromosome (data not shown). There 
are conserved estrogen response elements and transcription factor binding sites within 
ECR 5 and 6 in mouse and human proximal promoter regions. The human and murine 
PEMT gene contains additional EREs including a consensus ERE in a distal 
promoter/enhancer region approximately 7.5kb from TSS-B. The human promoter A 
region contains a CpG island and an experimentally validated 600 bp RNA polymerase II 
binding site (Pol 9419, p<0.00001) (Figure 2-3, Table 2-2) (Carroll et al., 2006). ECR 
browser, rVista TFBS search engine, Dragon ERE Finder, and TRANSFAC were used to 
identify ECRs, EREs, and TFBS respectively.  Each evolutionarily conserved region is 
outlined and double-underlined, italicized sequences correspond to nucleotides that differ 
from the estrogen response element consensus sequence. Underlined, italicized letters 
indicate transcription start sites for each proximal promoter region denoted A, B, C.  
aMotif Abbrevations for gene names are from LocusLink 
(www.ncbi.nlm.nih.gov/LocustLink/list.cgi; last accessed 01/02/07 
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Evolutionarily 
Conserved Region 
aMotifs Position Sequence 
 Human 
 PPARA 
-13233 TGATCT 
 
ECR 1 [-13399--13206] 
SP1 -13118 CCACAGCCCC 
  ERE 
-11388 TT-GGTCA-GGC-TGGTC-TT 
 ECR 2 [
-10919--10748] MYB -10839 GGCCAGTTC 
  ERE 
-10266 TT-AGTCA-CGC-TGGTC-TC 
 
Pol II 
binding site 
-9038 (bp 17,435,552-17,436,153) 
 CpG island 
-8774 CpG Repeat 
 Exon 1 
-9151  
Transcript A: 
NM_148172 
ECR 3 [-9246--9038] 
TSS A -9205 TTCCGGGGG (bp 17,435,719) 
  ERE 
-7647 GG-GGTCA-TGA-TCACC-TC 
 Consensus ERE 
-7401 CG-GGTCA-GGG-TGACC-CT 
  ERE 
-6707 GA-GACCA-GCC-TGACC-AA 
  ERE 
-5879 CG-GGGTA-TCT-TGACT-GC 
 FOXA1 
-3309 AAGTTGTTTCCATT 
 MYB 
-3264 AAACTGCCA 
 SOX6 
-3190 TGCATTGTTATCA 
 
ECR 4 [-3324--2994] 
GATA -3186 TGTTATCATT 
  SP1 
-862 GTGGCGTGAT 
  AP1 
-386 CTGACTCCT 
  AP1 
-206 CCCGAGTCAGC 
Transcript B:  
NM_007169 TSS+1 
+1 TTGTCCATG (bp 17,426,514) 
 TSS B 
+40 GACCACAA (bp 17,426,470) 
 Exon 2 +50  
 C/EBP +175 AAATTACCA 
 AP1 +631 CATTAGTCATT 
 ERE 
+725 TG-AGACA-GGC-TGACC-TG 
 
ECR 5 [-35-+1073] 
ERE +741 GA-GGCCA-TTG-GGACC-TG 
Transcript C:  
NM_148173 TSS C 
+5010 TGTGGGCGA (bp 17,421,504) 
 
ECR 6 [+5192-+5579] 
GATA +5284 TTTTATCTTC 
  ERE 
+5476 TG-GGCTA-CGT-GGACC-CC 
 Mouse 
 ECR 1 [
-12997--12808] Ppar-α -12,980 AGATCA 
  Sp1 
-12,884 CCCACC 
 ECR 2 [-11,874--11,709 Ppar- α -11,788 AGGTCA 
Transcript A  TSS A -9602 CATCAGATA (bp 59,659,083) 
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Evolutionarily 
Conserved Region 
aMotifs Position Sequence 
 ECR 3 [
-9592--9382] CpG island 
-9622--
9169 CpG repeats 
 Consensus ERE 
-7919 TA-GGTCA-GGA-TGACC-TT 
 ECR 5 (
-190-+884) TSS B (+1) +1 CCCAGTGTG (bp 59,649,481) 
Transcript B:  
NM_008819  TSS B 
+110 TTCCTTCTG (bp 59,649,379) 
  Ap1 
+429 CGTTAGTCACT 
  ERE 
+790 TG-AGGCA-GGC-TGACC-AG 
  ERE 
+813 CA-GGGCA-CGG-GGACC-TG 
  ERE 
+5150 TT-AGTCA-TGT-TGGCT-GC 
 ECR 6 (+4848-+5243) Gata +5441 CTTTTATCTTC 
Transcript C  TSS C +5147 GCTGATCTC (bp 59,644,334) 
  ERE 
+5192 TG-GGTTA-CAT-GGACC-CC 
  ERE +5780 GG-TGTCA-AGG-TGACC-TA 
  ERE 
+5860 AA-GACCA-CTG-TGACC-TC 
  ERE 
+7961 CA-GGTGG-GCC-TGACC-CT 
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Identification of an evolutionarily shared promoter framework in the PEMT gene.  In 
orthologous promoters, elements important for transcriptional regulation may be expected 
to be conserved during evolution (Elnitski et al., 2003).  Evolutionarily conserved regions 
(ECRs) were identified from two species (Homo sapiens and Mus musculus) in the 
PEMT promoter(s) by using the comparative genomics tool ECR Browser (as described 
in “Experimental Procedures”). We determined that the PEMT gene promoters contain 
six evolutionarily conserved regions within the region encompassing the three TSS 
predicted for the PEMT gene in each species (Figure 2-3, Table 2-2). The region 
containing this cluster of ECRs is approximately 18 kb for each organism with ECR 6 
overlapping the TSS of the shortest predicted transcript for each and ECR 1 being 4 kb 
upstream of NM_148172 (human) and 9.7 kb of transcript A (mouse). No other ECRs 
were found in the 15 kb upstream of ECR 1 in the mouse or within 29 kb of the human 
ECR 1. Within these conserved regions predicted transcription factor binding sites are 
likely to be conserved (Table 2-2). 
 Approximately 1% of previously identified EREs in human genes have 
counterparts at similar positions in their mouse orthologs. (Bourdeau et al, Mol 
Endocrinol, June 2004, 18(6):1411–1427).  Since conservation of EREs may indicate a 
functional role of these elements, we searched for the presence of conserved EREs with 
less than 9 kb difference in distance from their respective transcriptional start sites.  For 
estrogen binding-site predictions we used the previously described ERE model (Bajic et 
al., 2003) and Ap1 and Sp1 binding-site position weight matrices from the TRANSFAC 
database (Heinemeyer et al., 1999). We identified one perfect consensus estrogen 
response element approximately 7.5 kb from transcription start site B, TSS (+1), in both 
 52
                                         
the human and murine PEMT promoters. In the murine Pemt gene promoter region we 
identified seven imperfect EREs differing from the consensus by 1-3 nucleotides, three of 
which are located in ECRs in close proximity to TSS B and TSS C (Figure 2-3, Table 2-
2).  The human PEMT promoter region contains eight imperfect estrogen response 
motifs, three of which occur in an evolutionarily conserved region in close proximity to 
Promoter B (TSS B) and Promoter C (TSS C) (Figure 2-3, Table 2-2).  We also found 
several AP-1, SP-1 and FOXA1 sites in these evolutionarily conserved regions.   
 DISCUSSION 
 Choline is derived not only from the diet, but as well from de novo synthesis of 
phosphatidylcholine catalyzed by PEMT (Zeisel, 2006). We have previously reported that 
when deprived of dietary choline, men and postmenopausal women are more likely to 
develop fatty liver or muscle damage compared to pre-menopausal women (Fischer et al., 
2007).   In the present study, we observed that estrogen, at doses bracketing physiological 
concentrations in humans (0-100 nmol/L), caused a marked up-regulation in PEMT 
mRNA expression and enzyme activity, and that the PEMT gene has motifs (Walter et 
al., 1985) that may act as EREs in its promoter regions. This observation may help to 
explain why premenopausal women usually do not develop organ dysfunction when fed a 
diet low in choline (Fischer et al., 2007); they have estrogen-induced increased capacity 
for endogenous biosynthesis of the choline moiety.   
 Pregnancy and lactation are times when demand for choline is especially high. 
Indeed,  transport of choline from mother to fetus (Sweiry et al., 1986; Sweiry and 
Yudilevich, 1985) depletes maternal plasma choline in humans (McMahon and Farrell, 
1985).  Thus, despite an apparent enhanced capacity to synthesize choline, the demand 
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for this nutrient is so high that stores are depleted (Zeisel et al., 1995).  Because milk 
contains a great deal of choline, lactation further increases maternal demand for choline 
resulting in further depletion of tissue stores (Holmes-McNary et al., 1996; Zeisel et al., 
1995).  Pemt -/- mice abort pregnancies around 9-10 days gestation unless fed 
supplemental choline (personal observation).  Women in the USA vary enough in dietary 
choline intake (from <300mg/d to >500 mg/d) to influence the risk that they will have a 
baby with a birth defect; low dietary intake of choline during pregnancy was associated 
with a 4-fold increased risk of giving birth to an infant with a NTD (Shaw et al., 2004) 
and 1.5-fold increased risk for orofacial clefts (Shaw et al., 2006). Choline nutriture 
during pregnancy is especially important because it influences brain development in the 
fetus (Albright et al., 1999a; Albright et al., 2005; Albright et al., 2001; Albright et al., 
2003; Albright et al., 1999b; Albright et al., 1998; Craciunescu et al., 2003; Meck and 
Williams, 1997; Meck et al., 1988; Meck and Williams, 2003b; Mellott et al., 2004; 
Niculescu et al., 2006; Pyapali et al., 1998).  These observations suggest that women 
depend on high rates of endogenous biosynthesis of choline induced by estrogen, as well 
as on dietary intake of choline to sustain normal pregnancy. It is biologically plausible 
that, during evolution, appropriate mechanisms were developed to assure that young 
women are less susceptible to dietary choline deficiency and have adequate stores of 
choline prior to, and during pregnancy.    
Our observation that PEMT gene expression in mice and humans is induced by 
physiological concentrations of estrogen in humans (0-100 nmol/L) (Peck et al., 2002) 
correlates with the previous finding that estrogen increases PEMT activity in liver of the 
bird (Vigo et al., 1981; Vigo and Vance, 1981a, b), the rat liver (Young, 1971) and the rat 
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pituitary (Drouva et al., 1986; Drouva et al., 1987).  The classic actions of estrogen occur 
through its receptors ERα  and ERβ  which bind as homodimers or heterodimers to EREs 
in the promoters of many estrogen-responsive genes (Walter et al., 1985). The consensus 
ERE (PuGGTCAnnnTGACCPy) is an inverted palindromic sequence separated by three 
intervening nucleotides (Walter et al., 1985). This motif is usually surrounded by 50-
nucleotide flanking regions that contain other transcription factor binding sites (Tang et 
al., 2004). Imperfect ERE half site motifs (ERE1/2) also bind with ERα  and ERβ 
(Agarwal et al., 2002; Lopez et al., 2002; Xie et al., 1999).  It is noteworthy that the 
majority of known estrogen responsive genes contain imperfect EREs that differ from the 
consensus sequence (Driscoll et al., 1998).  EREs are usually found within -10 to +5 kb 
of transcriptional start sites and approximately 1% of elements appear to be conserved in 
the flanking regions of orthologous human and mouse genes (Bourdeau et al., 2004).  
Functional evolutionarily conserved EREs are most abundant in the 0 to +1 kb region 
around transcriptional start sites (Bourdeau et al., 2004).  Estrogen also can mediate its 
effect on proximal gene promoters from distances up to 10 kb by acting as an enhancer 
element (Bourdeau et al., 2004). This seems to be especially true when estrogen response 
motifs are located in the proximal gene region. EREs that are located far away from the 
promoter of a single gene can interact synergistically with EREs in the proximal 
promoter by DNA looping (Sathya et al., 1997). 
In mice, we found three conserved EREs at position +799 bp and +822 bp 
downstream of the TSS B and +66 bp upstream of TSS C. In humans, we found three 
conserved EREs at positions +725 bp and +741 bp downstream of TSS B and +466 bp of 
TSS C.  One of the ERE1/2 we found was embedded in an Alu repeat sequence. Alu 
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elements, the most abundant interspersed repeats in the human genome, have repeatedly 
been found to be involved in gene rearrangements in humans (Norris et al., 1995). 
Ubiquitous presence of Alu repeats and their specific properties suggest a number of 
functions for the Alu elements, one of which is the introduction of functional estrogen 
response elements into gene promoters (Norris et al., 1995). Finally, not all genes that are 
regulated by estrogen contain an ERE. Estrogen may regulate these target genes through 
interactions with other transcription factors such as activator protein 1, AP-1 (Vigo et al., 
1981; Vigo and Vance, 1981a, b), NF-κB (Drouva et al., 1987), or specific factor, Sp-1 
(Walter et al., 1985), and FoxA1 (Carroll et al., 2005; Laganiere et al., 2005).  We found 
several AP1, FOXA1, and SP1 sites in mouse and in human conserved promoter regions 
as well as in non-conserved regions.   
It was previously reported that the murine Pemt gene encodes one major transcript 
and that transcription was initiated from a single promoter (Walkey et al., 1996).  Both 
EST and CAGE analysis suggests the existence of three transcripts for the murine Pemt 
gene and for its human ortholog.  There is a cluster of ECRs within the putative promoter 
region containing the multiple TSS for each species and many conserved predicted 
binding sites for transcription factors within these ECRs and throughout the sequence 
analyzed above.  Based on multiple similarities in gene and protein structure, it is 
reasonable to predict that the murine and human PEMT genes are regulated in a similar 
manner.   
This report is the first to identify a possible mechanism through which estrogen 
induces PEMT expression and may explain the observation that premenopausal women 
are relatively resistant to choline deficiency. Future studies may include measuring the 
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abundance of the three PEMT transcripts in human and murine hepatocytes cultured in 
the presence and absence of 17-β-estradiol in order to determine whether estrogen 
treatment causes alternative promoter use and/or splicing. We are currently determining 
whether recently identified single nucleotide polymorphisms that increase women’s 
dietary requirement for choline (da Costa et al., 2006) work by altering estrogen-
mediated induction of the PEMT gene.  
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ABSTRACT  
Studies in mammals indicate a connection between estrogen status and resistance 
to choline deficiency syndrome (CDS), but the nature of this interaction is not 
understood.  Synthesis by hepatically expressed phosphadylethanolamine N-
methyltransferase (PEMT) constitutes the only de novo source of choline and is regulated 
by estrogen.  In humans, pre-menopausal women are relatively resistant to CDS 
suggesting young women have an enhanced capacity to generate choline de novo.  We 
identified a polymorphism highly associated (p<0.0001) with risk of CDS in a subset of 
premenopausal women which falls within 1kb of a key estrogen receptor (ER) regulatory 
region in the PEMT gene.  Hepatocytes homozygous for the risk allele are not estrogen 
responsive and exhibit decreased ER-DNA enrichment in the PEMT locus.  We propose a 
model in which an allele-specific ablation of ER-DNA interactions in a key regulatory 
region in the PEMT locus leads to a decrease in PEMT gene expression, thereby 
conferring risk of CDS in women. 
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INTRODUCTION  
Humans fed a choline deficient diet develop liver and muscle damage 
characterized by hepatosteotosis, liver ALT/AST enzyme leakage, elevated CPK levels, 
muscle cell apoptosis and lymphocyte cell death (subsequently referred to as choline 
deficiency-induced syndrome, CDS)  (da Costa et al., 2006b; Li et al., 2005; Zeisel, 
2006).  Although choline deficiency syndrome is consistently observed in men and post-
menopausal women, more than half of young women seem to be resistant to symptoms 
associated with low dietary choline.  However, approximately 44% of young women do 
develop choline deficiency (Fischer et al., 2007; Zeisel, 2008).  Synthesis of choline by 
liver, catalyzed by phosphadylethanolamine N-methyltransferase (PEMT) constitutes the 
only de novo source of the choline moiety.  PEMT message is synthesized from three 
promoters which direct expression of two isoforms (Shields et al., 2001).  Since 
endogenous production of choline may protect from CDS, we had previously examined 
the regulation of PEMT and demonstrated that PEMT is regulated by estrogen in human 
and mouse hepatocytes (Resseguie et al., 2007).  Based on this finding, we hypothesized 
that premenopausal women may be protected from CDS by estrogenic regulation of 
PEMT.  We examined the association of single nucleotide polymorphisms (SNPs) in the 
PEMT locus and found that premenopausal women harboring a SNP in the PEMT 
promoter are 25 times as likely to develop CDS as non-carriers (da Costa et al., 2006a). 
Although we had demonstrated that estrogen can regulate PEMT in hepatocytes, 
the specific mechanism for this regulation remains unknown.  Estrogen receptor mediates 
gene regulation by estrogenic hormones by directly interacting with DNA.  In order to 
comprehensively identify these sites of estrogen receptor/DNA contact, chromatin 
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immunoprecipitated (ChIP) with anti-estrogen receptor antibody has been analyzed by 
DNA microarrays (chip) (ChIP-on-chip) (Carroll et al., 2006; Gao et al., 2008; Kwon et 
al., 2007; Lin et al., 2007).  Examination of these data sets failed to reveal sites of 
estrogen receptor interaction near the PEMT locus.  However, these studies were 
performed in breast cancer cells and mouse liver cells. 
In order to determine the mechanism whereby the PEMT gene is regulated by 
estrogen in humans, we identified sites of ER-α binding to chromatin throughout the 
PEMT locus and examined estrogen regulation of the various PEMT transcripts.  Using 
an expanded panel of SNPs we narrowed the CDS susceptibility locus to eleven strongly 
linked SNPs spanning a region of 70.5 kilobases (kb) in the promoter regions and first 
and second intron of the PEMT gene.  We identified ER-α binding in a region of the 
PEMT gene located in the first intron of the PEMT A transcript and –40 bp 5’ of the 
transcriptional start site for PEMT B.  The intronic site is within 1 kb of the SNP most 
highly associated with CDS in women (rs4646343 (C/T); p=0.0001).  Using allele-
specific quantitative PCR (qPCR), we found decreased estrogenic activation of the PEMT 
gene from the risk allele.  To identify the functional polymorphism, we examined ER-
DNA interactions for the SNPs within the ER-α binding site that are in linkage 
disequilibrium (LD) with the most strongly susceptibility-associated SNP, rs4646343, in 
human hepatocytes and found reduced enrichment across this region in subjects 
homozygous for the risk allele relative to protective allele carriers.  
Taken together, our results suggest that SNPs within a critical estrogen regulatory 
region of the PEMT locus abrogate estrogenic regulation of PEMT, explaining how 
genetic variation can influence gender-specific dietary choline requirements.  
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MATERIALS AND METHODS  
ChIP-chip and ChIP-qPCR.  Chromatin prepared from formaldehyde-fixed primary 
hepatocytes was immunoprecipitated with a mixture of two anti-ER-α antibodies (Ab-10, 
Neomarkers; HC-20, Santa Cruz) as previously described (Carroll et al., 2006; Lee et al., 
2006).  Chromatin was analyzed by qPCR or by microarray hybridization as described 
previously (O'Geen et al., 2006).  Immunoprecipitated chromatin, as well as 
unfractionated input control chromatin, were fluorescently labeled and hybridized to a 
custom designed array (Nimblegen) which tiled 400 kb of the PEMT locus as well as 
several ER-α binding sites identified in other studies, (Carroll et al., 2005; Carroll et al., 
2006; Kwon et al., 2007; Lin et al., 2007) with 60-nt oligonucleotide overlapping 
isothermal probes after masking for repetitive regions.  We identified regions of 
enrichment by the intersection of two independent methods.  Using SignalMap 
(Nimblegen), we filtered for peaks with peak height enrichment ratio > 2.0; peak width > 
200 bp.  Chromatin was isolated from human hepatocytes derived from two different 
organ donors.  Statistical analyses were performed using Student’s t test comparison for 
unpaired data.  
Construction of plasmids and luciferase reporter assay.  ER-α ChIP binding sites were 
amplified from human liver genomic DNA by PCR and cloned into the pGL4-SV40 
vector (an SV40 promoter cloned upstream of pGL4-Basic (Promega)).  Sites were 
sequenced using a capillary sequencing machine (model 3100, Applied Biosystems) at 
the University of North Carolina at Chapel Hill Genome Analysis Facility.  Human 
primary hepatocytes, grown in hormone-depleted medium for at least 2 days, were co-
transfected with the ChIP- ER-α constructs and HSV-TK renilla with JETPEI hepatocyte 
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transfection reagent (Genesee Scientfic).  24 hours after transfection, cells were treated 
with 100 nM Moxestrol (MOX) for 24 hours, and cell lysates were harvested and 
assessed for firefly and renilla luciferase activity using the Dual Luciferase Reporter 
Assay system (Promega).  The data represent the average of four individual experiments. 
Transcript-Specific Gene Expression.  Primary human hepatocytes were isolated and 
cultured as described previously (Resseguie et al., 2007).  Briefly, hepatocytes were 
cultured for 24 hours in hormone-free media in 6-well collagen coated plates (BD 
biosciences) prior to treatment.  Cells were treated with 100nM MOX (Steraloids) for 4-
hour, 8-hour, and 24-hour time points.  RNA was isolated at each time point using 
RNeasy kit (Qiagen).  RNA was analyzed by quantitative PCR (Taqman,Applied 
Biosystems) with probes specific for each PEMT transcript (Transcript A: NM_148172: 
assay ID Hs01002998_m1; Transcript B: NM_007169: assay ID Hs00200354_m1; 
Transcript C NM_148173: custom assay ID 4331348).  To determine the absolute copy 
number of the target transcripts, we generated cDNA standards from human liver RNA, 
SuperScript III First (SSIII) Strand synthesis kit (Invitrogen), for each transcript.  429-bp 
cDNA fragments unique to each PEMT transcript were cloned into a TOPOII TA 
(Invitrogen), linearized with KpnI, gel purified and quantitated.  A standard curve for 
each transcript was generated (Figure 3-1).  The copy number of unknown samples 
(RNA extracted at various time points from human hepatocytes) was determined by 
linear regression analysis utilizing transcript specific standard curves.  To correct for 
differences in both RNA quality and quantity between samples, the expression levels of 
transcripts of interest were normalized to the housekeeping gene, GAPDH, and expressed 
a gene expression ratio change. 
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Figure 3-1.  Validation of Transcript Specific Gene Expression Using Real-Time 
Quantitative PCR. 
 
(A) Real-time PCR was performed with Taqman assays (Applied Biosystems) specific 
for each PEMT transcript: Transcript A: NM_148172: assay ID Hs01002998_m1; 
Transcript B: NM_007169: assay ID Hs00200354_m1; Transcript C: NM_148173: 
custom assay ID 4331348.  To determine the absolute copy number of the target 
transcripts, we generated cDNA standards for each transcript.  (B) A standard curve for 
each transcript was generated using serial dilutions of cloned products ranging from 1 or 
10 to 109 molecules/µl.  The copy number of unknown samples (RNA extracted at 
various time points from human hepatocytes) was determined by linear regression 
analysis utilizing the transcript-specific standard curve.  The limit of detection was ~1300 
copies per 150 ng cDNA for each transcript-specific standard (R2=0.999).
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Mapping Choline-Deficiency Syndrome Risk Haplotype in PEMT locus.  Humans eating 
diets deficient in the essential nutrient choline can develop organ dysfunction.  We 
hypothesized that common SNPs in genes involved in choline metabolism influence the 
dietary requirement of this nutrient.  Fifty-seven humans were fed a low choline diet until 
they developed organ dysfunction or for up to 42 days.  We tested DNA SNPs for allelic 
association with susceptibility to developing organ dysfunction upon subjection to a 
choline-deficient diet.  We identified a SNP in the promoter region of the 
phosphatidylethanolamine N-methyltransferase gene (PEMT; -744 G-->C; rs12325817) 
for which 18 of 23 carriers of the C allele (78%) developed organ dysfunction when fed a 
low choline diet (odds ratio 25, P=0.002) (da Costa et al., 2006a).  DNA was isolated 
from women (n=31) and men (n=26) who participated in the human choline study.  DNA 
was genotyped for a selection of SNPs in the PEMT locus using a custom bead array 
(Goldengate, Illumina).  SNPs selection was based on the TAMAL algorithm which 
selects SNPs in genes that likely affect function of the gene (e.g. predicted 
transcriptionally active regions, exonic (non-synonymous), transcription factor binding 
sites) (Hemminger et al., 2006).  Fisher’s exact test was used to determine statistical 
significance of SNP association with organ dysfunction. 
Allele Specific Gene Expression.  For allele imbalance experiments, we genotyped human 
liver donors for rs897453 (G/A; located in exon 3 of the PEMT gene common to all three 
transcripts) and rs4646343 (C/A; risk allele (A) highly associated with susceptibility 
(p=1x10-9) to CDS in women (as described above) and within 1kb of the PEMT intron 
1A ERα binding cluster).  SNP rs897453 is highly associated with SNP rs4646343 
(p<1x10-5) using qPCR (Assays-on-Demand SNP Genotyping assay, Applied 
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Biosystems) and the following Taqman primer-probe assays: SNP rs897453 (assay ID: 
C___7443062_1_); SNP rs4646343 (assay ID: C___9246129_10).  To quantify 
differences in allelic expression, we then generated a standard curve by mixing genomic 
DNA from homozygous risk individuals (rs4646343 (A/A)) and homozygous protective 
individuals (rs4646343(C/C)) at five different ratios in a TaqMan assay for exonic SNP 
rs897453 (Figure 3-2).  RNA was isolated from hepatocytes with RNeasy kit (Qiagen) 
and cDNA was generated using SSIII First Strand synthesis kit (Invitrogen).  Using real-
time qPCR and these standard curves, we were able to deduce the ratios of gene 
expression between the two alleles by measuring the fluorescent intensity of the two 
alleles in cDNA samples as described previously (Lo et al., 2003).  RNA expression was 
normalized by comparing to the allele-specific (FAM) 6-carboxyfluorescein 
intensity/VIC (a proprietary dye) intensity) gDNA quantitation from heterozygous 
subjects.  The average gDNA ratios were equilibrated to 50% for each allele and the same 
factor was applied to cDNA ratios.  Results are expressed as a percent of relative risk 
allele expression.  For determination of hormone mediated allele-specific expression, 
hepatocytes were treated with 100 nM MOX for 24h as described above.  The levels of 
risk allele expression from nine hepatocytes donors were calculated.
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Figure 3-2.  Validation of Standard for Detection of Allele-Specific Gene Expression.  
SNP rs897453 is within a transcribed region of the PEMT gene (exon 3) that is common 
to all transcripts and is associated with SNP rs4646343 (a SNP associated with risk of 
developing choline deficiency syndrome in women deprived of choline (p=1x10-9)).  To 
estimate allele-specific differences in PEMT gene expression, we created a standard 
curve by combining genomic DNA from two individuals at various ratios that were 
homozygous for the risk allele and homozygous for the protective allele.  A Taqman SNP 
Genotyping Assay for rs897453, in which the FAM probe is specific for the protective 
allele and the VIC probe is specific for the risk allele, was used to estimate the percent 
abundance of each allele at each ratio as described previously (Lo et al., 2003).  Using 
trend analysis, we determined that we could detect quantifiable differences between the 
VIC and FAM alleles (R2=0.961).
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Transcript-specific allele imbalance experiments were performed with primer-probe sets 
unique for each transcript (as described above) in hepatocytes that were homozygous for 
the risk allele (n=5), homozygous for the protective allele (n=6), and heterozygous for the 
risk/protective allele (n=5). 
Allele Specific ChIP.  Primers were designed (Primer 3, (Rozen and Skaletsky, 2000) to 
amplify regions of approximately 100 bp in close proximity to SNPs within ER binding 
regions and a negative control region (region of the genome not suspected to bind any of 
the transcription factors of interest).  ChIP qRT-PCR experiments were performed as 
described above except 30 µg of chromatin was used for the chromatin IP experiments 
from subjects homozygous for the risk (n=5) and protective allele (n=6) rs4646343 as 
well as for heterozygous subjects (n=4).  ChIP-chip experiments were performed in a 
subject homozygous for the risk allele and in a subject homozygous for the protective 
allele.  To validate SNP status and to identify potentially new SNPs, the 2.2 kb intron 1A 
region was sequenced in human hepatocytes and in subjects from the human choline 
study who were homozygous for the rs4646343 risk (A/A) and protective allele (C/C).  
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RESULTS  
Identification of ER-α Binding Sites in PEMT Locus in Human Hepatocytes 
Chromatin isolated from 17-beta estradiol (E2)-treated primary human 
hepatocytes was immunoprecipitated with an ER-α specific antibody as described 
previously.  Enriched chromatin and unfractionated input control DNA chromatin were 
hybridized to a custom Nimblegen-Roche microarray that comprehensively tiled virtually 
the entire PEMT gene with 60-bp overlapping, isothermal probes.  Previous genome-wide 
ER-α ChIP-chip studies reported that only 4% enrichment occurred at proximal promoter 
regions for all genes and had identified six ER-α binding sites within 200 kbp of the 
PEMT promoter at the following chromosomal coordinates (bp) relative to transcription 
start site (TSS) A (Carroll et al., 2006): 
Peak 1: {bp 17,599,362-17,599,962; +1.6 x105 bp TSSA} 
Peak 2:  {bp 17,574,823-17,575,536; +1.39 x105 bp TSSA} 
Peak 3: {bp 17,572,850-17,573,450; +1.37 x105 bp TSSA} 
Peak 4: {bp 17,541,224-17,541,831; +1.05 x105 bp} 
Peak 5: {bp 17,535,860-17,536,461; +1.0 x105 bp TSSA} 
Peak 6: {bp 17,448,820-17,449,421; +1.3 x104 bp TSSA} 
In light of this, we designed our arrays to tile 340 kb flanking the genes.  Another 
genome-wide promoter ChIP-chip study, also performed in breast cancer cells, identified 
enrichment at PEMT promoter A (NM_148172) (Kwon et al., 2007).  In contrast, a 
genome-wide identification of ER-α sites in mouse liver reported that almost 50% of ER-
α-binding regions overlap with genes, including 8% that overlap with exons (Gao et al., 
2008).  In order to identify putative sites of estrogen receptor interaction, we designed a 
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finely tiled array covering virtually the entire PEMT locus.  Using SignalMap 
(Nimblegen), we filtered for peaks with peak height enrichment ratio > 2.0; peak width > 
200bp.  A total of 7 binding sites were identified and were all located within the PEMT 
gene.  The data from the two human hepatocyte donors highly correlate with 
approximately 86% (6/7 peaks identical) overlap of binding sites (Figure 3-3, A and B).  
As positive controls, we also tiled several regions found to bind ER-α in MCF-7 cells.  
We found that approximately 60% of the positive control gene exhibited ER-α 
enrichment. 
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Figure 3-3.  ER-α Enrichment Regions in the Human PEMT Gene 
A) We tiled 340 kbp of the human PEMT gene and identified seven regions that were 
significantly enriched with ER-α by ChIP-chip.  B) A 20 kb wide view of the probe 
signals is illustrated.  The majority of the ER-α regions identified on the array were 
within the PEMT gene, including a region (Peak 4), which contains a consensus 
ERE/FOXA site.  C) We validated the regions identified on the array using ChIP coupled 
to real-time PCR and found that the peaks within intron 1A and the site at promoter B 
were significantly enriched with ER-α complex in the presence of E2 (n=3, *p<0.05; 
two-tailed; paired-Student’s test). 
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regions also exhibited ER-α enrichment in our experiments (data not shown). 
To validate the sites identified on the array, we performed three independent ChIP 
assays in primary human hepatocytes in presence or absence of E2 followed by real-time 
PCR (Figure 3-3, C).  The results of the ChIP-qPCR suggest the major sites of 
enrichment, which include a cluster of contiguous binding events within intron 1A and 
within promoter B.  The cluster of peaks within intron 1A, which spans ~2.2 kb, was 
divided into four regions.  Each site was validated by RT-PCR.  The segmented regions 
exhibited between 4 to 11-fold enrichment (p<0.05) in the presence of E2, with the 
exception of the peak that overlapped exon 1a (Peak 1).  These sites were located 
approximately 7.8kb 5’ from the transcription start site for PEMT B.  Although we 
densely tiled the region spanning the PEMT gene, the limiting resolution of this assay 
(approximately 250bp) makes it difficult to precisely identify the binding site.  The 
region annotated as Peak 4 within this cluster contained an evolutionarily-conserved 
consensus ERE (GGTCA-nnn-TGACC) and a proximal FOXA1 site.  (See Table 3-1 for 
chromosomal positions of validated ER-α regions relative to TSS B.)
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Table 3-1.  Genomic Coordinates of ER Binding Regions, SNPs, and Transcription 
Factor Binding Sites 
 
Using ChIP-chip we identified 7 regions in the PEMT locus enriched with ER-α 
annotated as Peaks 1-7.  Using ChIP-qPCR and gene-reporter assays, we narrowed down 
the critical ER regulatory region to the intron1a cluster (Peaks 2-4).  This region was 
sequenced.  Transcription factor binding sites were identified with TRANSFAC motif 
finder.  The minor allele for each SNP is in bold, underlined, and italicized.  All SNP 
sequences are given for (+) strand orientation; however in text the sequences for each 
SNP are given for (-) strand due to anti-sense orientation of the PEMT gene.  SNPs with 
linkage disequilibrium (r2) data relative to rs4646343 (Hapmap.org) are presented in the 
last column.  The majority of the hepatocyte organ donors from which data were obtained 
were of European descent, therefore the r2 values are presented for Utah residents with 
ancestry from northern and western Europe (CEU). SNPs rs4646343 and rs12325817 
(shown in red) are associated with CDS in women (p<0.0001). 
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ER Binding 
Site 5’ 3’ 
Size 
(bp) Sequence 
r2 {CEU} 
(rs464343)
TSS A 17435719     
Peak 1 17435563 17435779 216   
Peak 2 17434730 17435315 585   
un-annotated 
SNP 17434794   G/A  
rs4646340 17434740   G/A 0.659 
Peak 3 17434183 17434679 496   
rs4646341 17434535   C/T 0.671 
Peak 4 17433337 17434067 730    
 
un-annotated 
SNP 17434032   C/G  
rs4646342 17433997   C/T 0.858 
ERE 17433899   GGTCA-GGG-TGACC  
rs46464459 17433811   A/G 0.834 
FOXA1 17433694 17433717  TCCCT-GGCCTG-GGAGAGT-TGCAAG  
rs4646343 17432802   C/A 1.0 
rs12325817 17427244   C/G  
TSS B 17426470     
Peak 5 17426283 17426611 328   
TSS C 17421504     
Peak 6 17421386 17421571 185   
Peak 7 17420889 17421092 203   
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ER-α Sites in Intron1A Mediate Transcriptional Activation  
To examine whether ChIP ER-α binding sites harbor transcriptional enhancer 
activities, we cloned the ER-α enrichment cluster in intron 1A containing Peaks 2-4 and 
the region within Promoter B, Peak 5, isolated from human liver genomic DNA upstream 
of the pGL4-SV40 luciferase reporter.  Hormone-depleted primary human hepatocytes 
were transiently transfected with these constructs were treated with MOX for 24 hours 
and then assayed for luciferase activity.  Since the prototypical estrogen, E2, is rapidly 
metabolized in p450-containing liver cells (Barkhem et al., 1997; Mattick et al., 1997), 
we stimulated cells with the synthetic estrogen MOX (Barkhem et al., 1997; Kanamori et 
al., 2000; Mattick et al., 1997; Petz et al., 2002).  The region containing peaks 2, 3 and 4 
can mediate estrogenic activation (Figure 3-4).  Peak 5 stimulated basal transcription 
from the SV40 promoter, but was incapable of mediating estrogen activation.  Peaks 2 
and 3, as well as the ERE region containing Peak 4, demonstrated estrogen-mediated 
induction.  This suggests that multiple regions located in intron 1 can mediate estrogen 
induction, even in the absence of a consensus ERE.
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Figure 3-4.  Intron 1A ER-α ChIP Binding Sites are Functional Transcriptional 
Enhancers 
 
ER binding sites were cloned into the pGL4-SV40 luciferase reporter construct and 
transfected into primary hepatocytes that were grown in hormone-depleted medium for at 
least two days.  The cells were then either left untreated or treated with 100 nM MOX for 
24 hours before harvesting for luciferase activity.  pGL4-SV40 and pGL4-TFF1 (TFF1 
promoter cloned into a pGL4-luc construct) were used as negative and positive controls, 
respectively.  The cells were also cotransfected with the -TK renilla vector as an internal 
control for transfection efficiency.  The data represent the average of four individual 
experiments (*=p<0.05).
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Estrogen Regulation of PEMT Gene is Transcript-Specific 
Previous studies of PEMT activation by estrogen were unable to examine which 
promoters were induced and which isoforms were made.  To further characterize 
estrogenic regulation of the gene, we utilized transcript-specific primer-probe sets.  To 
accurately quantify expression level (gene copy number) differences between transcripts, 
we also generated cDNA standards for each transcript.  To assess the kinetics of PEMT 
induction for each transcript, we harvested mRNA at various time points.  Transcriptional 
changes at 4 hours represent immediate transcriptional activation whereas activation at 8 
and 24 hour time points suggest delayed activation.  Transcript A was the most abundant 
of the three transcripts in un-stimulated cells with approximately 750,000 copies per 150 
ng cDNA (Figure 3-5, A), however it was not responsive to MOX treatment any time 
point tested (Figure 3-5, A and C).  In contrast, transcript B was induced at all time 
points.  Hepatocytes contained approximately 300,000 copies per 150 ng cDNA in 
untreated cells, but this level increases to ~500,000 and ~750,000 at 4 and 8 hours, 
respectively, of MOX treatment (Figure 3-5, A).  Transcript B became the predominant 
transcript in cells 4 hours after MOX treatment and was almost equivalent to expression 
of transcript A by 24 hours.  Transcript C was the least abundant transcript.  Nonetheless, 
treatment with MOX markedly induced gene expression by 8 hours (~15,000 copies per 
150 ng cDNA) and was maximally induced by 24 hours (~18,000 copies per 150 ng 
cDNA) (Figure 3-5, B).  These results suggest that transcript B is an early estrogen 
target, whereas transcript C is likely a late target, and that transcript A is not significantly 
regulated by estrogenic mechanisms. 
91
Figure 3-5.  Estrogen Regulation of PEMT Gene Expression is Transcript-Specific 
Using RT-PCR, we measured transcript-specific gene expression of PEMT transcripts A, 
B, and C.  A) Transcript A is the most abundant transcript (~6.5 x 105 copies per 150 ng 
cDNA) but is not responsive to hormone treatment.  Transcript B is significantly induced 
in response to hormone treatment at both early and late time points (~3.0x105 copies per 
150 ng cDNA in untreated cells vs. ~7.0 x 105 copies per 150ng cDNA in treated cells).  
B) Transcript C was the least abundant transcript but was significantly induced in 
response to hormone treatment by 8 and 24 hours (~5.0 x103 copies per 150 ng cDNA).  
C) Transcript B was induced by approximately 2.5-fold by 4 hours and maximally by 8 
hours whereas transcript C was induced 3-fold by 8 and 24 hours.  Results are expressed 
as ratio-fold change in gene expression relative to untreated samples, normalized to 
GAPDH. (n= 4/point; * = p<0.05 by paired, two-tailed Students t-test).   
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The ER-Binding Region is Proximal to an Organ Dysfunction-Associated SNP 
Our previous study of choline deprivation in human subjects identified a specific 
SNP that was highly associated with CDS in women (SNP rs12325817; p=1x10-9 ) (da 
Costa et al., 2006a).  To further define the region of the PEMT locus associated with risk 
for CDS in women, we genotyped subjects for an extended panel of SNPs that span the 
PEMT locus using a custom Goldengate Illumina Bead array.  Eleven SNPs were found 
to be significantly associated with susceptibility to CDS in women but not men (Figure 
3-6, A).  The minor allele of SNP rs4646343 (C/A) was most strongly associated with the 
CDS phenotype (p=1x10-7).  SNP rs464343 is located approximately 1 kb from the ER-α 
enriched region in intron 1A (Figure 3-6, B).  Other SNPs within this binding region are 
in high LD with rs464343.  In addition, a SNP located in exon 3, rs897453, was also 
found to be statistically significantly associated with rs464343 (p=1x10-6) and 
rs12325817 (p=1x10-4).  Exonic SNP rs897453, a missense polymorphism (Val-Ile) was 
not found to be significantly associated with CDS in women relative to men (p=0.0812).  
The identification of a SNP in a common coding exon permits detection of allele-specific 
expression.
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Figure 3-6.  SNP Highly Associated with CDS in LD with PEMT-ER Region 
A) A study conducted in a cohort of women (n=31) and men (n=26) identified SNP 
rs12325817 (p=1x10-9 ) as being strongly associated with CDS in women (da Costa et al., 
2006a).  To determine whether this SNP acts a regulatory SNP or is just in LD with a 
regulatory SNP, we genotyped these subjects for a panel of SNPs that spanned the PEMT 
locus (Custom Goldengate Illumina Bead array) to identify regions associated with organ 
dysfunction.  Eleven SNPs were found to be significantly associated with susceptibility to 
CDS in women but not men.  A map of these SNPs is displayed graphically as a function 
of chromosomal position (x-axis) relative to association with CDS (1-probability; y-axis).  
SNP rs4646343 was most strongly associated with the phenotype (p=1x10-7) and an 
exonic SNP rs897453 was found to significantly associated with rs4644343 (p=1x10-6) 
and rs12325817 (p=1x10-4).  B) SNP rs464343 is located approximately 1 kb from the 
intron 1A cluster of ER-α enrichment and is in high LD with several SNPs within this 
binding region (statistical cut-off: p<0.05; Fishers exact test).  
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Risk Allele is Not Estrogen Responsive 
The minor allele (A) of SNP rs897453 was highly associated with the risk allele 
(A) of SNP rs4646343 but not with risk of CDS in women relative to men in the human 
choline study cohort.  To determine if the risk allele was associated with aberrant PEMT 
gene expression, we genotyped human liver organ donors to determine their SNP status at 
rs4646343 and rs897453 (based on the association that minor allele A is highly 
associated with risk allele A).  We then generated a standard curve by mixing gDNA 
from homozygous risk allele subjects with homozygous protective subjects at the several 
ratios to validate the reliable detection of differences between the risk and protective 
allele (r^2=0.961, Figure 3-2). Quantitative PCR of cDNA from estrogen treated and 
non-treated heterozygous subjects followed by linear regression analysis permitted us to 
estimate the relative expression of the risk allele versus protective allele in nine subjects.  
We found that, for all transcripts, in the absence of estrogen treatment, the risk allele was 
under-expressed by ~4% relative to the protective allele (p=0.01) and under-expressed by 
~8% (p=0.001) after treatment with MOX (Figure 3-7, A). 
To explore whether over-expression of the protective allele may compensate for 
the lower expression of the risk allele, we compared total gene expression levels in 
human hepatocytes from three genetic backgrounds (i.e. homozygous for protective 
(C/C), risk (A/A) and heterozygous (C/A) alleles) before and after treatment with 
estrogen.  We found that in hepatocytes homozygous for the risk allele, transcripts B and 
C were not hormone-inducible at any time point tested (p<0.02) (Figure 3-7, B).
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Figure 3-7.  Risk Allele is Not Estrogen Responsive 
A) To assess differences in allelic expression, we utilized RT-PCR and isolated hepatic 
cDNA from MOX-treated and non-treated heterozygous (risk SNP rs4646343; exonic 
SNP rs897453) subjects (n=9) and used linear regression analysis to estimate the relative 
% expression of the risk allele versus protective allele.  In the absence of MOX treatment, 
the risk allele was under-expressed by ~4% relative to the protective allele (p=0.01) and 
under-expressed by ~8% (p=0.001) after treatment with MOX.  Results are presented as 
an average +/- SD of the nine subjects and individually.  B) Total gene expression levels 
were determined by quantitative RT-PCR in human hepatocytes treated with estrogen 
representative of all three genetic backgrounds (homozygous for protective (C/C), risk 
(A/A) and heterozygous (C/A) alleles).  Transcripts B and C in hepatocytes that were 
homozygous for the risk allele were not estrogen inducible at any time point tested 
(p<0.02).  There was a trend of reduced estrogen-mediated induction in heterozygous 
hepatocytes that approached statistical significance (n= 6 protective homozygous 
subjects; 5 heterozygous subjects; 5 risk homozygous subjects; *p=paired student’s t-test; 
**p= 0.002). 
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Allele-Specific ER-α Enrichment within Intron 1A Binding Region. 
As previously noted, the SNP most highly associated with CDS in women 
(rs4646343 (C/A); p=0.0001) is within 1kb of an ER-α binding region.  This 2.2 kb 
region contains three sites (annotated as Peak 2, 3 and 4) that can act as a transcriptional 
enhancer.  Peak 4 contains a consensus ERE and FOXA1 site.  To determine if SNP 
status affects ER-α DNA binding at any of these sites, we performed quantitative ChIP in 
primary hepatocytes from subjects from the three genetic backgrounds (homozygous for 
risk allele, homozygous for the nonrisk allele, and heterozygous).  We found decreased 
enrichment at all sites in chromatin from subjects homozygous for the risk allele 
compared to homozygous protective and heterozygous subjects.  In contrast, ER-α 
binding at Peaks 4 and 5 was identical in treated vs. non-treated hepatocytes homozygous 
for the risk allele (Figure 3-8, A).  In order to evaluate for additional SNPs in this region 
that may not have been represented in the Illumina bead array, we sequenced the 2.2 kb 
region from several subjects.  We identified six SNPs that differ between the 
homozygous risk and protective subjects.
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Figure 3-8  Allele Specific ER-α Enrichment within Intron 1A Binding Region  
A) SNP rs4646343 ((C/A); p=0.0001) is within 1kb of a region enriched with ER-α 
binding in the PEMT gene.  This 2.2 kb region contains three ER-α binding sites 
(annotated as Peak 2, 3 and 4).  To determine if SNP status affects ER-DNA binding at 
any of these sites, we performed ChIP-qPCR in hepatocytes representative of all three 
genetic backgrounds.  We found decreased enrichment at all sites tested in subjects that 
were homozygous for the risk allele relative to homozygous protective and heterozygous 
subjects; however there was no difference in enrichment between treated and non-treated 
hepatocytes that were homozygous for the risk allele at Peaks 4 and 5.  B) By sequencing, 
we identified six SNPs that differ between the homozygous risk and protective subjects.  
These include SNPs (rs4244599 (A/G), rs4646342 (C/T), rs4646340 (A/G), rs4646341 
(C/T) and two previously unidentified SNPs at Chr17 nt positon 17434032 (C/G)) and 
17434794 (G/A).  Comparison of ChIP-chip results between subject #1 (homozygous for 
the risk allele) and subject #2 (homozygous for the protective allele) reveals less ER-α 
enrichment in subjects homozygous for the risk allele across the intron1A region, 
however Peak 3 is absent in subject #1.  ChIP-qPCR in hepatocytes homozygous for the 
risk allele did exhibit enrichment at the Peak 3 site, albeit less enrichment than in 
homozygous protective hepatocytes and in heterozygous subjects. 
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This includes four previously annotated SNPs, rs4244599 (C/G), rs4646342 (A/T), 
rs4646341 (G/C), rs4646340 (G/A), and two previously unidentified SNPs at Chr17 nt 
positons 17434032 (C/G) and 17464794 (G/A).  There was a perfect concordance 
between the SNPs among homozygous risk subjects and homozygous protective subjects 
(Figure 3-8, B).  In Figure 3-8 we present ChIP-chip data from the subject that is 
homozygous for the risk allele (subject #1) versus a subject that is homozygous for the 
protective allele (subject #2).   There is less enrichment in subjects homozygous for the 
risk allele across the intronic region ER region however Peak 3  is absent in subject #1.  
ChIP-qPCR in hepatocytes that were homozygous for the risk allele did exhibit 
enrichment at the Peak 3 site, albeit less than in homozygous protective hepatocytes and 
in heterozygous subjects. 
DISCUSSION 
Choline is an essential nutrient in humans.  Insufficient dietary choline results in a 
syndrome that includes muscle and liver dysfunction characterized by hepatosteotosis, 
liver ALT/AST enzyme leakage, elevated CPK levels, muscle cell apoptosis, 
inflammation, and hepatocyte cell death.  We previously identified a subset of young 
women who are protected against CDS relative to men and post-menopausal women.  
Since PEMT functions as the only source of de novo choline, we looked for an 
association between SNPs in the PEMT locus and CDS. We found that premenopausal 
women harboring a PEMT promoter SNP are twenty five times as likely to develop CDS 
as non-carriers of this SNP.(da Costa et al., 2006a)  
The PEMT gene is estrogen responsive in a dose-dependent manner.(Resseguie et 
al., 2007)  However, the mechanism whereby estrogen regulates the gene remains 
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underdetermined.  In this study we sought to identify regions in the PEMT locus that 
could be estrogen regulatory and to determine if SNPs, previously identified as 
conferring an increased risk to CDS in women, affect estrogenic regulation of PEMT 
gene expression. 
Examining the entire PEMT locus by ChIP-chip we identified several ER-α 
enriched regions in the PEMT gene, specifically implicating a critical regulatory region 
located in intron 1 of the A transcription start site, 7500 nt upstream of the transcriptional 
start site of transcript B.  We were able to resolve this region into three potential binding 
sites—annotated as Peak 2-4.  Prototypically estrogen receptor binds a 13 bp palindromic 
repeat and its binding seems to be facilitated by proximal binding of FOXA1, a 
transcription factor shown to be essential for ER gene regulation at distal sites. (Carroll et 
al., 2005)  We found that peak 4 contains a canonical ERE as well as a FOXA1 site.  
These sites were not identified in a previous genome-wide examination for ER-α binding 
sites in the estrogen responsive breast tumor cell line MCF-7, suggestive of potential 
tissue specificity. (Carroll et al., 2006)  Peak2/3 as well as Peak 4 are independently able 
to act as enhancers.  A site in the proximal promoter for transcript B was also found to be 
bound by ER, by ChIP-chip and ChIP-qPCR.  However, this site lacked the ability to act 
as an enhancer in transfection-based reporter assays in primary hepatocytes.  This 
suggests that this region does not have the ability to act alone to initiate transcription and 
may physically interact with the more distal enhancer region.  Similarly, there was a peak 
in promoter C that may play the same role.  This hypothesis is corroborated by the 
finding that transcripts B and C are estrogen inducible transcripts in contrast to transcript 
A.  Although transcript A is the most abundant transcript in untreated hepatocytes, in the 
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presence of estrogen transcript B is strongly induced and becomes the majority PEMT 
transcript.  Transcript C is also strongly induced, but was expressed at much lower levels 
relative to A and B, and thus is unlikely to contribute significantly to an estrogen-
mediated increase in PEMT activity.  Transcripts B and C encode the same ER-directed 
isoform, PEMT II which is functionally distinct from PEMT I. Previously it was shown 
that PEMT II is highly expressed in female mouse liver, but not in male liver suggesting 
a gender specific role. .(Noga and Vance, 2003) 
We genotyped the cohort of men and women from a clinical study on human 
dietary choline requirements (da Costa et al., 2006a) for a subset of SNPs in the PEMT 
locus to identify potential regions  associated with susceptibility to CDS.  A subset of 
SNPs was strongly associated with susceptibility to CDS in women but not in men, 
suggesting that these regions may be critical to PEMT expression in women.  We 
compared the risk associated SNPs with the regions of ER binding identified by ChIP-
chip and found that the SNP most highly associated with susceptibility to CDS in women 
(rs4646343 (C/A); p=0.0001) was within 1kb of peak 4.  A SNP located in LD with 
rs4646343 provided us the opportunity to examine allele-specific expression in 
heterozygous hepatocytes.  We found that the risk allele was significantly under-
expressed both in the presence and absence of hormone treatment.  In hepatoyctes 
homozygous for the risk allele, PEMT was not estrogen-responsive.  We examined the 
influence of these SNPS on ER binding to the transcriptionally active regions identified 
in transcript A, exon 1. We found that Peak 4, which contains an ERE and FOXA1 site, 
was not enriched with ER-α in hepatocytes homozygous for the risk allele.  Peak 4 
contains three SNPs that are in high linkage disequilibrium with the most strongly risk-
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associated SNP---rs4646343—in human hepatocytes.  Peak 5 was also diminished in the 
context of the rs4646343 risk SNP, supporting the hypothesis that the critical ER-α 
binding site in peak 4 interacts with proximal promoter B and both sites of interaction are 
disrupted by the SNP.  We suggest that potential regulatory SNP(s) reside within Peak 4, 
and these alter binding affinity for transcription factor ER-α, prevent looping to Promoter 
B and result in decreased estrogen-mediated induction of PEMT transcripts B and C.  
The results presented here provide a potential mechanism which explains how 
SNPs within a critical estrogen regulatory region of the PEMT locus abrogate estrogenic 
regulation of PEMT.  This study is the first to propose a model which explains how 
genetic variation influences gender specific requirements for choline. 
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 CHAPTER VI 
OVERALL DISCUSSION 
IMPORTANCE OF CHOLINE 
Choline is essential for normal function of all cells. (Zeisel and Blusztajn, 1994)  
It is the major source of methyl-groups in the diet. Following its oxidation to betaine, 
choline participates in the methylation of homocysteine to form methionine. (da Costa et 
al., 2005).  In addition, choline is used for the biosynthesis of cell membranes, bioactive 
phospholipids, and is the precursor molecule of the neurotransmitter acetylcholine. 
(Zeisel and Blusztajn, 1994)  Insufficient dietary choline results in a syndrome 
characterized by hepatosteotosis (due to lack of phosphatidylcholine which limits the 
export of excess triglyceride from liver in lipoproteins)), liver ALT/AST enzyme leakage, 
elevated CPK levels, muscle cell apoptosis, inflammation, and hepatocyte cell death.  
(Albright et al., 2005; Albright et al., 1996; Albright and Zeisel, 1997; Buchman et al., 
1995; da Costa et al., 2004; Fischer et al., 2007; James et al., 1997; Zeisel, 2000)  Shaw 
and colleagues, studying pregnant women in California observed intakes of choline in 
25% of the population that were less than needed to prevent birth defects in their fetuses. 
(Shaw et al., 2006; Shaw et al., 2004) 
The only source of choline other than diet is from the de novo biosynthesis of 
phosphatidylcholine catalyzed by phosphatidylethanolamine-N-methyltransferase 
(PEMT) in liver.  When fed a diet deficient in choline, Pemt −/− mice developed fatty 
liver, severe liver damage and died; a choline supplemented diet prevented this (Walkey 
et al., 1998) and reversed hepatic damage if begun early enough. (Waite et al., 2002)  It is 
now accepted that the PEMT pathway is not just a minor pathway that backs up the CDP-
choline pathway for phosphatidylcholine biosynthesis. Pemt −/− mice have lower choline 
pools in liver despite being fed sufficient or supplemental amounts of dietary choline,  
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suggesting that choline production by PEMT is a significant source of choline relative to 
dietary intake. (Zhu et al., 2003)   
ESTROGEN AND THE REQUIREMENT FOR CHOLINE 
A subset of premenopausal women, relative to males and postmenopausal women, 
are resistant to developing choline deficiency syndrome. (Fischer et al., 2007)  Treatment 
with estradiol at doses bracketing physiological concentrations in humans (0 − 100 
nmol/l), causes a marked up-regulation in PEMT mRNA expression and enzyme activity 
in human hepatocytes. (Resseguie et al., 2007)  Thus, premenopausal women have an 
enhanced capacity for de novo biosynthesis of choline moiety.  
Although the PEMT gene is estrogen responsive in a dose-dependent manner; the 
mechanism whereby estrogen regulates the gene remains undetermined.  The human 
PEMT gene encodes three unique transcripts, A (NM_148172), B (NM_007169), and C 
(NM_148173) which encode two different protein isoforms. PEMT I, encoded by 
transcript A, localizes to the endoplasmic reticulum whereas PEMT II, synthesized from 
transcripts B and C, are found primarily in the mitochondrial associated membrane, a 
subfraction of the endoplasmic reticulum. 
Recently, chromatin immunoprecipitation (ChIP) has been used coupled with 
DNA microarrays (chip) (ChIP-on-chip) to pursue whole-genome identification of ER-
binding sites in intact chromatin of cultured breast cancer cell lines.(Carroll et al., 2005; 
Carroll et al., 2006) (Kwon et al., 2007; Lin et al., 2007)  A genome-wide ChIP-on-chip 
study identified DNA regions that bind ER-α in intact chromatin from mouse liver, and  
reported that  approximately 1.2% of the ER-α binding regions overlapped with human 
studies. (Gao et al., 2008) 
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Examining the entire PEMT locus by ChIP-chip we identified several ER-α enriched 
regions in the PEMT locus, specifically identifying a critical regulatory region located in 
intron 1 of the A transcription start site, 7500 nt upstream of the transcriptional start site 
of transcript B.  We were able to resolve this region into three potential binding sites—
annotated as Peak 2-4.  We found that peak 4 contained a canonical ERE as well as a 
FOXA1 site, which are essential to ER gene regulation.  A site in the proximal promoter 
for transcript B, was found to be bound by ER, by ChIP-chip and ChIP-qPCR.  However, 
this site lacked the ability to act as an enhancer in transfection-based reporter assays in 
primary hepatocytes.  This suggests that this region does not have the ability to act alone 
to initiate transcription and may physically interact with the more distal enhancer region.  
This hypothesis is corroborated by the finding that transcripts B and C are estrogen 
inducible transcripts in contrast to transcript A.  Although transcript A is the most 
abundant transcript in untreated hepatocytes, in the presence of estrogen,  transcript B is 
strongly induced and becomes the majority PEMT transcript.  Transcript C is also 
strongly induced, but was expressed at a much lower level relative to A and B and, thus, 
is unlikely to contribute significantly to an estrogen-mediated increase in PEMT levels.  
Transcripts B and C encode the same endoplasmic reticulum-directed isoform, it is 
possible that the role of PEMT II is functionally distinct from PEMT I.  This isoform 
specificity has been suggested by previous findings that PEMT II which is highly 
expressed in female mouse liver but in not male liver suggesting a gender specific role 
for this isoform.(Noga and Vance, 2003) 
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GENETIC VARIATION IN CHOLINE REQUIREMENTS 
Though some humans develop fatty liver, as well as liver and muscle damage 
when fed a low choline diet, others do not.  Even among premenopausal women who 
should be resistant to choline deficiency, a subset develops organ dysfunction when 
deprived of choline. (Fischer et al., 2007)  Genetic variation likely underlies these 
differences in dietary requirements.  Several pathways influence how much choline is 
required from diet and functional SNPs in genes for these pathways might be of 
importance. Specifically, polymorphisms in the PEMT gene might alter endogenous 
synthesis of choline thereby influencing choline dietary requirements. 
The human PEMT gene is highly polymorphic, and one of the primary goals of 
this dissertation is the identification of SNPs that affect choline biosynthesis.  We believe 
that people with such SNPs will be more vulnerable to developing organ dysfunctions 
when dietary choline intake is marginal. We found that premenopausal women harboring 
a PEMT promoter SNP are twenty five times as likely to develop CDS as are non-carriers 
of this SNP.(da Costa et al., 2006)  Given the sexual dimorphism in the effect of PEMT 
rs12325817, it is possible that this SNP or an associated SNP alters the estrogen 
responsiveness of the promoter.  The frequency of this variant allele was 0.74.   
We genotyped the cohort of men and women from the human choline study (da 
Costa et al., 2006) for a subset of SNPs in the PEMT locus to identify potential regions in 
the PEMT locus associated with susceptibility to CDS.  A subset of SNPs was strongly 
associated with risk in women but not in men suggesting these regions may be critical to 
PEMT expression in women.  We compared the risk-associated SNPs to with the regions 
of ER-α binding identified by ChIP-chip and found that the SNP most highly associated 
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with CDS in women (rs4646343 (C/A); p=0.0001) is within 1kb of peak 4.  A SNP 
located in linkage disequilibrium with rs4646343 provided us the opportunity to examine 
allele-specific expression in heterozygous hepatocytes.   
A recent genome-wide association (GWA) study profiled more than 39,000 
transcripts and genotyped approximately 800,000 unique SNPs in more than 400 human 
liver samples to determine the association between allelic imbalance in gene expression 
in the human liver and the association to various diseases (Schadt et al., 2008).  In order 
to map cis-acting regulatory SNPs, this group identified genes which exhibit allelic 
imbalance in gene expression by collating transcript expression levels in the human liver 
samples with each of the SNPs in the analysis.  Results from this study did not support 
the hypothesis that PEMT gene expression is under cis regulatory genetic control in 
human liver.  We found that the risk allele was significantly under-expressed both in the 
presence and absence of hormone treatment.  Since we determined that PEMT A is the 
most abundant transcript in human hepatocytes but is not induced by estrogen, we 
hypothesize that the allelic imbalance we observed between risk and protective allele 
primarily affects PEMT transcripts B and C and that transcript A remains unchanged.  A 
potentially greater reduction in transcript B and C expression levels would be not 
detected by the allele imbalance detection assay utilized by our experiments nor would 
this difference have been detected in the GWA study conducted by Schadt and 
colleagues, due to an inability tot discriminate between transcripts.  To further support 
our hypothesis that risk allele-associated under-expression is transcript-specific, we 
looked at total expression levels and found that neither PEMT transcript B or C were 
estrogen-responsive in hepatoyctes homozygous for the risk allele. 
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We examined the influence of these SNPS on ER binding to the transcriptionally 
active regions identified in transcript A, exon 1. We found that Peak 4, which contains an 
ERE and FOXA1 site, was not enriched with ER-α in hepatocytes homozygous for the 
risk allele.  Peak 4 contains three SNPs that are in high LD with the most strongly risk-
associated SNP---rs4646343—in human hepatocytes.  Peak 5 was also diminished in the 
context of the rs4646343 risk SNP, supporting the hypothesis that the critical ER-α 
binding site in peak 4 interacts with proximal promoter B and both sites of interaction are 
disrupted by the SNP. We suggest that potential regulatory SNP(s) reside within Peak 4, 
and these alter binding affinity for transcription factor ER-α, prevent looping to Promoter 
B and result in decreased estrogen-mediated induction of PEMT transcripts B and C.  
The results presented here provide a potential mechanism which explains how 
SNPs within a critical estrogen regulatory region of the PEMT locus abrogate estrogenic-
regulation of PEMT.  Characterizing estrogenic regulation of choline biosynthesis 
provides an explanation for studies that have reported that, in animal models, females are 
less sensitive to choline deficiency than are males because they have higher capacity to 
form choline de novo via the PEMT pathway. (Noga and Vance, 2003; Tessitore et al., 
2000)   
During pregnancy, choline stores become depleted and lactation further increases 
the demand for choline.(Zeisel et al., 1995)   Pregnant Pemt knockout females had the 
most severe triglyceride accumulation in liver as compared to males and non-pregnant 
females maintained on the same diet.(Zhu et al., 2003)   Studies conducted in 
collaboration with the March of Dimes, found that women in the lowest quartile of 
dietary choline intake, were 4 times as likely to have a baby with a neural tube defect. 
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(Shaw et al., 2006)  We propose that women with functional SNPs that affect estrogen 
regulation will be susceptible to CDS and will have an increased risk of having a baby 
with a neural tube defect.  This study is the first to propose a model which explains how 
genetic variation influences gender specific requirements for choline 
SUMMARY 
Studies aimed at defining the human dietary choline requirement underscore the 
importance of research exploring genetic and variation.  Choline is a major dietary source 
of methyl-groups (one of choline's metabolites, betaine, participates in the methylation of 
homocysteine to form methionine); also choline is needed for the biosynthesis of cell 
membranes, bioactive phospholipids and the neurotransmitter acetylcholine. A 
recommended dietary intake for choline in humans was set in 1998, and a portion of the 
choline requirement can be met via endogenous de novo synthesis of phosphatidylcholine 
catalyzed by phosphatidylethanolamine N-methyltransferase (PEMT) in the liver. Though 
many foods contain choline, many humans do not get enough in their diets. When 
deprived of dietary choline, most adult men and postmenopausal women developed signs 
of organ dysfunction (fatty liver, liver or muscle cell damage, and reduces the capacity to 
handle a methionine load, resulting in elevated homocysteine).  However, only a portion 
of premenopausal women developed such problems.  For the first time, we present 
evidence that choline biosynthesis is induced by estrogen and suggest that differences in 
dietary choline requirements occur because estrogen induces expression of the PEMT 
gene and allows premenopausal women to make more of their needed choline 
endogenously.  Further, we identified SNPs in an ER regulatory region that may affect 
estrogen-mediated induction of the PEMT gene.  We postulate that these SNPs are 
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responsible for the significant variation in the dietary requirement for choline observed in 
women. Preliminary studies conducted by members of our clinical research team, 
corroborate this hypothesis.  That is, we find that the administration of Premarin, an 
estrogen derivative, does not prevent CDS in post-menopausal homozygous for the risk 
allele. (manuscript in preparation).   
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 CHAPTER V 
FUTURE RESEARCH 
The preceding studies demonstrated that estrogen regulates the choline 
biosynthetic gene, PEMT and determined that regulation is conferred by a 2.2 kb region 
in intron 1A.  A SNP (rs4646343) which conferred risk to choline deficiency syndrome in 
women was associated with under-expression of the PEMT gene in response to estrogen 
treatment in human hepatocytes.  SNPs in linkage disequilibrium with rs4646343 that 
map to ER regulatory regions affect ER-DNA interactions.  Based on this work, the 
following areas are proposed for further investigation:  
I. Characterize SNP-ER Impact on Choline Biosynthesis in Human Hepatocytes.  
We observed that the PEMT gene is responsive to estrogen treatment and 
examined the entire locus by ChIP-chip. We identified several ER-α enriched regions in 
the PEMT locus specifically implicating a critical regulatory region located in intron 1 of 
the A transcription start site, 7500 nt upstream of the transcriptional start site of transcript 
B.  We were able to resolve this region into three potential binding sites—annotated as 
Peak 2-4.  We found that peak 4 contains a canonical ERE as well as a FOXA1 site and 
suggest that the effect may be conferred by the ERE-FOXA1 site within the ER-
α binding site.  Promoter B was also enriched with ER-α binding although gene reporter 
assays indicated that this region does not harbor independent transcriptional activity.  
Hepatocytes homozygous for the risk allele rs4646343 were not estrogen responsive.  
ER-DNA binding at Peaks 2-4 and at Promoter B was diminished in hepatocytes 
homozygous for the rs4646343 risk allele.  We sequenced this region and identified 6 
SNPs, 4 of which are in high LD (r2>0.6) with rs4646343.  We hypothesize that a 
regulatory SNP(s) within this region acts to prevent ER-DNA binding and potentially 
prohibits inter-chromosomal looping of the intronic binding site to Promoter B which 
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resulting in under-expression of the estrogen inducible transcripts B and C.  To examine 
the effects of genetic variation on the ER transactivational capabilities of the risk 
haplotype vs. the protective haplotype, we will clone the region spanning Promoter B 
through intron 1A from human hepatocytes homozygous for the risk allele and 
homozygous for the non-risk allele into luciferase report constructs.  Site-directed 
mutagenesis will be used to examine the effects of individual SNPs within the ER-α 
binding region.  Following transient transfection into primary human hepatocytes and 
induction with estrogen, we can measure luciferase activity to evaluate the individual 
contributions of each SNP and as well as the combined effect impact on promoter 
activities. We predict that the risk haplotye will result in decreased estrogen mediated 
promoter B induction.   
Chromosome conformation capture assays (3C) have been utilized to explore long 
range estrogen-induced control of gene expression which is mediated through direct 
physical interactions between gene promoters and estrogen regulatory elements. (Perillo 
et al., 2008)   This inter-chromosomal looping interaction can be detected using the 
chromosome conformation capture (3C) methodology. (Gondor et al., 2008) Studies will 
be conducted too determine whether the causative SNP(s) prevent or decrease inter-
chromosomal interactions between the intron1A sites and Promoter B. We predict that 
intron 1A interactions with Promoter B would be absent in hepatocytes homozygous for 
the risk allele in the presence of estrogen.  Analogously, our allele specific ChIP findings 
demonstrated that hepatocytes homozygous for the risk allele were not enriched with ER-
α at Promoter B in the presence of estrogen treatment.  
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II. The Influence of PEMT Copy Number Variation on Choline Deficiency 
Syndrome in Women. 
 
The human genome shows extensive copy-number variation (CNV), the presence 
of variable numbers of copies of large, multi-kilobase genomic regions in the genomes of 
different individuals.  (Young et al., 2008)  It is reasonable to speculate that copy number 
variants which overlap genes have significant potential to influence gene expression at 
the transcriptional and translational levels.  The association of specific CNVs with 
clinical phenotypes makes it reasonable to hypothesis that CNVs in the PEMT locus 
could account for some of the variation we see in susceptibility to CDS in women. (Perry 
et al., 2007; Wong et al., 2007)   
A study using a whole-genome comparative genomic hybridization (CGH) array, 
which measured large scale (>40 kb) segmental gains and losses in >100 individuals 
identified a CNV spanning PEMT locus.  Of the 95 individuals analyzed, 3% of the 
subjects exhibited this genomic variant. (Figure 5-1) To determine if a CNV confers 
susceptibility to CDS, a robust method that allows for accurate quantitation of DNA copy 
number should be employed.   
CGH arrays and fluorescence in situ hybridization (FISH) are techniques that 
have commonly been used to detect CNVs in mammalian genomes. (Babovic-
Vuksanovic et al., 2004; Ishkanian et al., 2004) The resolution of CGH arrays is too low 
to detect microdeletions and microduplications (Mantripragada et al., 2004a; 
Mantripragada et al., 2004b) and would be too costly to screen large numbers of subjects.  
FISH is useful for regions that have previously been identified and is costly and time-
consuming.  Competitive PCR, a highly sensitive technique for detecting CNVs, 
accurately distinguishes normal copy number (2 copies) from a single copy deletion (1 
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copy) and a single copy gain (3 copies). (Williams et al., 2008) High-density SNP 
genotyping platforms, in which a signal intensity measure is summarized for each allele 
of a given SNP, are used to identify regions with multiple SNPs that fall within deletions 
or duplications. (Cooper et al., 2008)  Due to the high number of polymorphisms in LD 
within the PEMT locus, high-density SNP genotyping arrays may be a good method for 
copy number detection and analysis.(Locke et al., 2006)
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Figure 5-1.  CNV identified in the PEMT locus.  A whole-genome tiling BAC array 
CGH approach identified a segmental loss in in 3% of the study population in the PEMT 
gene spanning 44.5kb (Chr 17; bp 17,405,360—17,449,863).
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Using quantitative PCR, an established method for detection of CNVs, (Weksberg 
et al., 2005), we are currently developing an assay for detection of the PEMT CNV 
previously reported by Wong and colleagues.  This technique provides a quantitative 
measurement of DNA copy number and has several advantages, such as low technical 
difficulty, cost effectiveness and requires a fraction of the time required by FISH or array 
hybridizations.   
III. The Role of Estrogens on Pemt Expression in Fetal Mouse Brain 
  ER  and ER  are differentially expressed throughout the rodent brain. (Mitra et 
al., 2003; Shughrue et al., 1997) Estrogen enhances learning in a range of rodent memory 
tasks, including the Morris water maze and inhibitory avoidance tasks and the underlying 
mechanisms have been elucidated. (Frye and Rhodes, 2002; Li et al., 2004)(Adams et al., 
2004) Maternal dietary choline supplementation in rats results in lifelong cognitive and 
memory enhancement in the offspring. (Craciunescu et al., 2003)  Choline availability 
during fetal development is critical for the developing fetal brain (Albright et al., 1999a; 
Albright et al., 2001; Albright et al., 1999b); however the contribution of fetal Pemt 
derived PtdCho to the choline pool is unclear. (Blusztajn et al., 1985) Early studies in rat 
brain found that Pemt enzymatic activity was approximately 4-fold higher in neonatal 
than in adult brains. (Blusztajn et al., 1985). Brain development is perturbed in the 
Pemt−/− mouse, with increased cell proliferation in the fetal hippocampus and decreased 
expression of calretinin (a marker of GABAergic cell differentiation). (Zhu et al., 2004) 
Although the knockout mice had diminished choline and metabolite concentrations in 
fetal brain, unlike animals fed a choline-deficient diet, the Pemt−/− mice had increased 
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concentrations of S-adenosylmethionine in brain, with hypermethylated DNA and 
proteins. (Zhu et al., 2004) 
The effect of maternal estrogen on fetal brain development is not well established.  
Pregnancy provides a high progesterone and estrogen environment for both fetus and 
mother.  Understanding the impact of the hormones produced by the materno-feto-
placental unit on brain development is an area of active investigation.  Penn and 
colleagues at Standford School of Medicine report that many neurons in “non-sexually 
dimorphic” regions are responsive to these hormones, including cerebellar and 
hippocampal neurons.  We would like to extend our hepatic Pemt studies to the 
developing fetal brain.  If estrogen regulation of Pemt is important during development, 
then SNPs that have functional significance could perturb brain development.   
Preliminary studies in which we compared the relative Pemt expression levels in 
fetal vs. adult brain revealed that Pemt gene expression is significantly higher in fetal 
than in adult brain.  (Figure 5-2)  Briefly, whole brains were isolated from fetal and adult 
male C57Bl6 mice.  Brains were homogenized in lysis buffer and total RNA isolated 
(Qiagen’s RNasy kit) per manufacturer’s instructions.  RNA was reverse transcribed 
using Superscript III First Strand synthesis kit (Invitrogen) and amplified by PCR using 
ABI Prism 7900 sequence-detection system (Roche-Applied Biosystems, Foster City, 
CA).  Since stable gene expression of houskeeping genes varies between tissues and 
throughout development, we choose to normalize Pemt gene expression relative two 
house-keeping genes, namely b-actin (b-act) and hypoxanthine guanine phosphoribosyl 
transferase I (Hprt1).  Hprt1 is one of the most stably expressed genes in hippocampal 
neurons. (Santos and Duarte, 2008) The following gene-specific Taqman assays were 
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used for real-time PCR:  Pemt: Mm00839436_m1; b-act: Mm01205647_g1; and hrpt1: 
Mm01305687_g1. 
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Figure 5-2.  Pemt gene expression in fetal brain is markedly higher than in adult 
brain.  To determine relative Pemt gene expression levels in fetal and adult brain.  We 
performed Real time quantification of Pemt in mRNA isolated from fetal (E17) and adult 
whole brain.  We normalized Pemt gene expression relative to two house-keeping genes 
(A) hypoxanthine guanine phosphoribosyl transferase I (Hprt1) and (B). b-actin (b-act). 
Result are expressed as mRNA expression as a percent of control (Ctrl).  Results 
represent an average of three biological replicates.  (**p<0.001; as determined by 
Student's t-test performed on log-transformed expression data) 
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